High-density lipoprotein inhibits the oxidative modific

Lipids and Lipid Metabolism
1044, 275-283
DOI: 10.1016/0005-2760(90)90314-n

Citation Report

#	Article	IF	Citations
1	Protective effect of probucol on alloxan diabetes in rats. Diabetes Research and Clinical Practice, 1989, 7, 313-316.	1.1	16
2	Therapeutic perspectives in hyperlipidemic patients with diabetes mellitus. The Journal of Diabetic Complications, 1990, 4, 72-74.	0.2	2
3	Probucol does not alter acetylated low density lipoprotein uptake by murine peritoneal macrophages. Atherosclerosis, 1990, 80, 191-197.	0.4	11
4	Effect of probucol treatment on the susceptibility of low density lipoprotein isolated from hypercholesterolemic patients to become oxidatively modified in vitro. Atherosclerosis, 1990, 82, 43-51.	0.4	62
5	Macrophages and Oxidized Low Density Lipoproteins in the Pathogenesis of Atherosclerosis. Annals of Medicine, 1991, 23, 561-567.	1.5	88
6	A 21-aminosteroid inhibits oxidation of human low density lipoprotein by human monocytes and copper. Atherosclerosis, 1991, 90, 197-202.	0.4	12
7	Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Letters, 1991, 286, 152-154.	1.3	847
8	Modulation of low-density lipoprotein-induced inhibition of intercellular communication by antioxidants and high-density lipoproteins. Food and Chemical Toxicology, 1991, 29, 615-620.	1.8	16
9	Feasibility of using an oleate-rich diet to reduce the susceptibility of low-density lipoprotein to oxidative modification in humans. American Journal of Clinical Nutrition, 1991, 54, 701-706.	2.2	302
10	Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein.. Journal of Clinical Investigation, 1991, 88, 2039-2046.	3.9	669
11	Alteration of Serum Lipoprotein Metabolism by Polychlorinated Biphenyls and Methionine in Rats Fed a Soybean Protein Diet. Journal of Nutrition, 1991, 121, 925-933.	1.3	33
12	Antioxidants and atherosclerosis: A current assessment. Clinical Cardiology, 1991, 14, 25-30.	0.7	58
13	Role of oxidized low density lipoprotein in atherogenesis.. Journal of Clinical Investigation, 1991, 88, 1785-1792.	3.9	2,453
14	Gas phase oxidants of cigarette smoke induce lipid peroxidation and changes in lipoprotein properties in human blood plasma. Protective effects of ascorbic acid. Biochemical Journal, 1991, 277, 133-138.	1.7	472
15	More on Chewing the Fat. New England Journal of Medicine, 1991, 325, 1740-1742.	13.9	47
16	Effect of probucol dosage on plasma lipid and lipoprotein levels and on protection of low density lipoprotein against in vitro oxidation in humans.. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1992, 12, 318-324.	3.8	85
17	Binding of transition metals by apolipoprotein A-I-containing plasma lipoproteins: inhibition of oxidation of low density lipoproteins.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 6993-6997.	3.3	134
18	High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 10316-10320.	3.3	445

#	Article	IF	Citations
19	High-density lipoprotein antagonizes the inhibitory effects of oxidized low-density lipoprotein and lysolecithin on soluble guanylyl cyclase. Biochemical and Biophysical Research Communications, 1992, 182, 302-308.	1.0	30
20	Probucol reduces plasma and aortic wall oxysterol levels in cholesterol fed rabbits independently of its plasma cholesterol lowering effect. Atherosclerosis, 1992, 96, 125-134.	0.4	72
21	The effect of probucol on HDL-mediated sterol translocation and efflux from cells. Atherosclerosis, 1992, 94, 51-60.	0.4	7
22	Lipid peroxidation â€" a common pathogenetic mechanism?. Experimental and Toxicologic Pathology, 1992, 44, 169-181.	2.1	202
23	Malondialdehyde modification and copper-induced autooxidation of high-density lipoprotein decrease cholesterol efflux from human cultured fibroblasts. Lipids and Lipid Metabolism, 1992, 1125, 230-235.	2.6	70
24	The influence of medium components on Cu2+-dependent oxidation of low-density lipoproteins and its sensitivity to superoxide dismutase. Lipids and Lipid Metabolism, 1992, 1128, 50-57.	2.6	64
25	Oxidized HDL are much less cytotoxic to lymphoblastoid cells than oxidized LDL. Lipids and Lipid Metabolism, 1992, 1128, 163-166.	2.6	24
26	Modified apolipoprotein pattern after irradiation of human high-density lipoproteins by ultraviolet B. Lipids and Lipid Metabolism, 1992, 1128, 167-173.	2.6	22
27	Inhibition by serum components of oxidation and collagen-binding of low-density lipoprotein. Lipids and Lipid Metabolism, 1992, 1128, 211-219.	2.6	15
28	Increased oxidizability of plasma lipoproteins in diabetic patients can be decreased by probucol therapy and is not due to glycation. Biochemical Pharmacology, 1992, 43, 995-1000.	2.0	92
29	Cross-linking of apolipoproteins is involved in a loss of the ligand activity of high density lipoprotein upon Cu2+-mediated oxidation. FEBS Letters, 1992, 314, 199-202.	1.3	55
30	Antioxidant activity of high density lipoproteins in vivo. Bulletin of Experimental Biology and Medicine, 1992, 114, 960-963.	0.3	4
31	Free radicals promote modifications in plasma high-density lipoprotein: Nuclear magnetic resonance analysis. Free Radical Biology and Medicine, 1992, 12, 193-203.	1.3	45
32	Antioxidants: A biological defense mechanism for the prevention of atherosclerosis. Medicinal Research Reviews, 1993, 13, 161-182.	5.0	45
33	Is paraoxonase related to atherosclerosis. Chemico-Biological Interactions, 1993, 87, 161-171.	1.7	61
34	Oxidized LDL and atherogenesis: Relation to risk factors for coronary heart disease. Clinical Cardiology, 1993, 16, 3-5.	0.7	23
35	Malondialdehyde adducts to, and fragmentation of, apolipoprotein B from human plasma. Clinica Chimica Acta, 1993, 218, 39-46.	0.5	19
36	Effect of platelet activating factor on the kinetics of LDL oxidation in vitro. FEBS Letters, 1993, 317, 202-206.	1.3	5

#	Article	IF	Citations
37	Inhibition of low density lipoprotein oxidation by thyronines and probucol. Biochemical Pharmacology, 1993, 45, 753-762.	2.0	29
38	Two independent macrophage receptors for acetylated high-density lipoprotein. Lipids and Lipid Metabolism, 1993, 1170, 143-150.	2.6	17
39	High-density lipoprotein subfractions. American Journal of Medicine, 1993, 94, 636-645.	0.6	80
40	Effects of the synthetic anti-oxidant, probucol, on the U937 monoblastoid cell line. Atherosclerosis, 1993, 99, 1-13.	0.4	3
41	Antioxidative activity of high density lipoproteins in vivo. Atherosclerosis, 1993, 100, 13-18.	0.4	115
42	Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis, 1993, 104, 129-135.	0.4	737
43	Copper- and malondialdehyde-induced modification of high density lipoprotein and parallel loss of lecithin cholesterol acyltransferase activation. Atherosclerosis, 1993, 104, 213-219.	0.4	49
44	How HDL protects against atheroma. Lancet, The, 1993, 342, 1315-1316.	6.3	28
45	Why Is Smoking a Major Risk Factor for Coronary Heart Disease in Hyperlipidemic Subjects?. Annals of the New York Academy of Sciences, 1993, 686, 66-69.	1.8	7
46	High density lipoprotein reverses inhibitory effect of oxidized low density lipoprotein on endothelium-dependent arterial relaxation.. Circulation Research, 1993, 72, 1103-1109.	2.0	141
47	Increased production rates of LDL are common in individuals with low plasma levels of HDL cholesterol, independent of plasma triglyceride concentrations.. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993, 13, 842-851.	3.8	17
48	Serum lipoproteins and hemostatic function in intermittent claudication.. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993, 13, 1441-1448.	3.8	39
49	Interaction of oxidized HDLs with J774-A1 macrophages causes intracellular accumulation of unesterified cholesterol.. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993, 13, 1334-1345.	3.8	34
50	Role of oxidised low density lipoprotein in atherogenesis. Heart, 1993, 69, S12-S18.	1.2	162
51	Comparison of supplementation of RRR-alpha-tocopherol and racemic alpha-tocopherol in humans. Effects on lipid levels and lipoprotein susceptibility to oxidation.. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993, 13, 601-608.	3.8	105
52	Two patterns of LDL metabolism in normotriglyceridemic patients with hypoalphalipoproteinemia.. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993, 13, 579-589.	3.8	12
53	Influence of the apoA-II gene locus on HDL levels and fatty streak development in mice.. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993, 13, 1-10.	3.8	126
54	The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochemical Journal, 1993, 294, 829-834.	1.7	293

#	Article	IF	Citations
55	Oxidative tyrosylation of high density lipoprotein by peroxidase enhances cholesterol removal from cultured fibroblasts and macrophage foam cells.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 6631-6635.	3.3	137
56	Effects of oleate-rich and linoleate-rich diets on the susceptibility of low density lipoprotein to oxidative modification in mildly hypercholesterolemic subjects.. Journal of Clinical Investigation, 1993, 91, 668-676.	3.9	333
57	Probucol Suppresses the Development of Chronic Renal Failure in Dahl Salt-Sensitive Rats: An Animal Model of Spontaneous Focal and Segmental Glomerulosclerosis. Nephron, 1994, 67, 125-126.	0.9	6
58	Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits.. Circulation, 1994, 90, 1935-1941.	1.6	180
59	Antibody Against Oxidized Low-Density Lipoprotein Predicting Myocardial Infarction. Archives of Internal Medicine, 1994, 154, 2605.	4.3	198
60	High-density lipoprotein stimulates endothelial cell movement by a mechanism distinct from basic fibroblast growth factor.. Circulation Research, 1994, 74, 1149-1156.	2.0	60
61	Oxidation of heparin-isolated LDL by hemin. The effect of serum components.. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994, 14, 1966-1975.	3.8	12
62	Coronary atherosclerotic wall thickening and vascular reactivity in humans. Elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis.. Circulation, 1994, 89, 2525-2532.	1.6	245
63	Lipids, Apolipoproteins and Lipoproteins. Developments in Cardiovascular Medicine, 1994, , 83-103.	0.1	10
64	Plasma triglycerides and three lipoprotein cholesterol fractions are independent predictors of the extent of coronary atherosclerosis.. Circulation, 1994, 90, 2230-2235.	1.6	122
65	Effects of phosphatidylserine on the oxidation of low density lipoprotein. International Journal of Biochemistry & Cell Biology, 1994, 26, 539-545.	0.8	4
66	Probucol scavenged 1,1-diphenyl-2-picrylhydrazyl radicals and inhibited formation of thiobarbituric acid reactive substances. Free Radical Biology and Medicine, 1994, 16, 201-206.	1.3	27
67	The protective role of high-density lipoprotein on oxidized-low-density-lipoprotein-induced U937/endothelial cell interactions. FEBS Journal, 1994, 221, 35-41.	0.2	58
68	Effect of cholesterol feeding on the susceptibility of lipoproteins to oxidative modification. Lipids and Lipid Metabolism, 1994, 1213, 207-214.	2.6	21
69	Malondialdehyde-modified high-density lipoprotein cholesterol: plasma removal, tissue distribution and biliary sterol secretion in rats. Lipids and Lipid Metabolism, 1994, 1214, 137-142.	2.6	12
70	Tocopherols and carotenes are differently distributed in subfractions of high-density lipoprotein. Lipids and Lipid Metabolism, 1994, 1210, 373-376.	2.6	7
71	Inhibitory effect of high-density lipoprotein on platelet function is mediated by increase in nitric oxide synthase activity in platelets. Life Sciences, 1994, 55, 1815-1821.	2.0	56
72	In vitro oxidised HDL is recognised by the scavenger receptor of macrophages: implications for its protective role in vivo. Atherosclerosis, 1994, 105, 179-189.	0.4	44

#	Article	IF	Citations
73	Measurement of antioxidant activity in lipoproteins using enhanced chemiluminescence. Atherosclerosis, 1994, 111, 79-89.	0.4	23
74	Increased oxidazability of plasma low density lipoprotein from patients with coronary artery disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1994, 1225, 200-208.	1.8	44
75	Identification of Proteins Associated with Apolipoprotein A-I-Containing Lipoproteins Purified by Selected-Affinity Immunosorption. Biochemistry, 1994, 33, 1988-1993.	1.2	57
76	ASCORBIC ACID AND PLASMA LIPIDS. Epidemiology, 1994, 5, 19-26.	1.2	33
77	Lipoprotein metabolism and its relationship to atherosclerosis. Medical Clinics of North America, 1994, 78, 1-20.	1.1	99
78	Diet and coronary heart disease: beyond dietary fats and low-density-lipoprotein cholesterol. American Journal of Clinical Nutrition, 1994, 59, 1117S-1123S.	2.2	88
79	Plasma Lipid Peroxidation and Hyperglycaemia: a Connection Through Hyperinsulinaemia?. Diabetic Medicine, 1995, 12, 802-808.	1.2	62
80	Prevention of atherosclerosis. Postgraduate Medicine, 1995, 98, 175-184.	0.9	17
81	Consumption of red wine with meals reduces the susceptibility of human plasma and low-density lipoprotein to lipid peroxidation. American Journal of Clinical Nutrition, 1995, 61, 549-554.	2.2	603
82	Rationale for Cholesterollowering Strategies. Current Problems in Cardiology, 1995, 20, 286-357.	1.1	1
83	Pathogenesis of atherosclerosis. American Journal of Cardiology, 1995, 76, 18C-23C.	0.7	134
84	Plasma cholesteryl ester transfer protein and highâ€density lipoproteins: new insights from molecular genetic studies. Journal of Internal Medicine, 1995, 237, 5-12.	2.7	72
85	Prevention of Cholesteryl Ester Accumulation in P388D1 Macrophage-Like Cells by Increased Cellular Vitamin E Depends on Species of Extracellular Cholesterol. Conventional Heterologous Non-Human Cell Cultures are Poor Models of Human Atherosclerotic foam Cell Formation. FEBS Journal, 1995, 233, 171-178.	0.2	31
86	Effect of sodium citrate on the rate of cholesterol esterification and on the formation of primary products of lipid peroxidation in human blood. Are these processes related?. Bulletin of Experimental Biology and Medicine, 1995, 120, 962-964.	0.3	0
87	Low-density lipoproteins inhibit histamine and NaNO2 relaxations of the coronary vasculature and reduce contractile function in isolated rat hearts. Heart and Vessels, 1995, 10, 249-257.	0.5	21
88	Decreased capacity to inhibit platelet hyperactivity and to stabilize prostacyclin of high-density lipoproteins in experimental diabetes. Acta Diabetologica, 1995, 32, 170-175.	1.2	2
89	Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures.. Journal of Clinical Investigation, 1995, 96, 2758-2767.	3.9	699
90	Atherogenic dyslipidemia: Lipoprotein abnormalities and implications for therapy. American Journal of Cardiology, 1995, 75, 45B-52B.	0.7	53

#	Article	IF	Citations
91	Inhibition of Lecithin-Cholesterol Acyltransferase and Modification of HDL Apolipoproteins by Aldehydes. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 1599-1606.	1.1	81
92	Lipoproteins Regulate C-Type Natriuretic Peptide Secretion From Cultured Vascular Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 1968-1974.	1.1	40
93	A Polymorphism of the Paraoxonase Gene Associated With Variation in Plasma Lipoproteins in a Genetic Isolate. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 89-95.	1.1	115
94	HDL Apolipoprotein A-I Attenuates Oxidative Modification of Low Density Lipoprotein: Studies in Transgenic Mice. Clinical Chemistry and Laboratory Medicine, 1995, 33, 721-5.	1.4	19
95	Cholesterol and the Coronary Endothelium. European Journal of Cardiovascular Prevention and Rehabilitation, 1995, 2, 180-188.	3.1	0
96	High-Density Lipoprotein Cholesterol, Plasma Triglyceride, and Coronary Heart Disease: Pathophysiology and Management. Advances in Pharmacology, 1995, 32, 375-426.	1.2	27
97	Inhibition of ADP-induced platelet aggregation by apoE is not mediated by membrane cholesterol depletion. Thrombosis Research, 1995, 80, 499-508.	0.8	11
98	Physicochemical changes in human high-density lipoproteins (HDL) oxidized by gamma radiolysis-generated oxyradicals. Effect on their cholesterol effluxing capacity. Lipids and Lipid Metabolism, 1995, 1255, 23-30.	2.6	66
99	Prevention of in vitro low-density lipoprotein oxidation by an albumin-containing Lp A-I subfraction. Lipids and Lipid Metabolism, 1995, 1255, 31-38.	2.6	20
100	Thyronines and probucol inhibition of human capillary endothelial cell-induced low density lipoprotein oxidation. Biochemical Pharmacology, 1995, 50, 1627-1633.	2.0	20
101	Combination therapy with probucol prevents adriamycin-induced cardiomyopathy. Journal of Molecular and Cellular Cardiology, 1995, 27, 1055-1063.	0.9	115
102	HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis, 1995, 115, 243-253.	0.4	410
103	Evaluation of oxidative stress in patients with hyperlipidemia. Atherosclerosis, 1995, 117, 61-71.	0.4	164
104	Paraoxonase: another factor in NIDDM cardiovascular disease. Lancet, The, 1995, 346, 856.	6.3	18
105	Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet, The, 1995, 346, 869-872.	6.3	337
106	Lipid peroxidation: A review of causes, consequences, measurement and dietary influences. International Journal of Food Sciences and Nutrition, 1996, 47, 233-261.	1.3	260
107	Erratum to â€œin vitro oxidised HDL exerts a cytotoxic effect on macrophagesâ€• Atherosclerosis, 1996, 127, 143.	0.4	0
108	Inhibition of ADP-induced platelet aggregation by apoE is not mediated by membrane cholesterol depletion. Thrombosis Research, 1996, 81, 597-606.	0.8	14

#	Article	IF	Citations
109	Pyrene lipids as markers of peroxidative processes in different regions of low and high density lipoproteins. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1996, 1315, 78-86.	1.8	17
110	Relative resistance of the hamster to aortic atherosclerosis in spite of prolonged vitamin E deficiency and dietary hypercholesterolemia. Putative effect of increased HDL?. Lipids and Lipid Metabolism, 1996, 1299, 216-222.	2.6	15
111	High-density lipoprotein: Relations to metabolic parameters and severity of coronary artery disease. Metabolism: Clinical and Experimental, 1996, 45, 1375-1382.	1.5	20
112	Reconstituted high density lipoprotein reduces the capacity of oxidatively modified low density lipoprotein to accumulate cholesteryl esters in mouse peritoneal macrophages. Atherosclerosis, 1996, 119, 191-202.	0.4	10
113	High density lipoproteins and coronary heart disease. Atherosclerosis, 1996, 121, 1-12.	0.4	383
114	The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis. Atherosclerosis, 1996, 125, 217-229.	0.4	26
115	High density lipoproteins increase cytoplasmic free calcium in bovine aortic endothelial cells. Journal of Lipid Mediators and Cell Signalling, 1996, 15, 5-15.	1.0	3
116	Reference intervals for plasma apolipoprotein A-1 determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study. Clinical Chemistry, 1996, 42, 507-514.	1.5	137
117	Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 11448-11453.	3.3	225
118	Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels.. Journal of Clinical Investigation, 1996, 97, 2917-2923.	3.9	531
119	Effectiveness of Low-Dose Crystalline Nicotinic Acid in Men With Low High-Density Lipoprotein Cholesterol Levels. Archives of Internal Medicine, 1996, 156, 1081.	4.3	35
120	[1] Apolipoproteins: Pathophysiology and clinical implications. Methods in Enzymology, 1996, 263, 3-32.	0.4	12
121	The role of oxidized lipoproteins in atherogenesis. Free Radical Biology and Medicine, 1996, 20, 707-727.	1.3	1,238
122	Oxidized low-density lipoprotein and atherosclerosis. International Journal of Clinical and Laboratory Research, 1996, 26, 178-184.	1.0	56
123	Estradiol-17Î² as an antioxidant: Some distinct features when compared with common fat-soluble antioxidants. Translational Research, 1996, 128, 367-375.	2.4	103
124	Reversal by high-density lipoprotein of the effect of oxidized low-density lipoprotein on nitric oxide synthase protein expression in human platelets. Translational Research, 1996, 127, 287-295.	2.4	29
125	Alteration of lipoproteins of suction blister fluid by UV radiation. Journal of Photochemistry and Photobiology B: Biology, 1996, 33, 233-238.	1.7	9
126	Flavonoids?Chemistry, metabolism, cardioprotective effects, and dietary sources. Journal of the European Ceramic Society, 1996, , 66-76.	2.8	291

#	Article	IF	Citations
127	Lipoprotein composition in NIDDM: effects of dietary oleic acid on the composition, oxidisability and function of low and high density lipoproteins. Diabetologia, 1996, 39, 667-676.	2.9	35
128	Extent of oxidative modification of low density lipoprotein determines the degree of cytotoxicity to human coronary artery cells.. Heart, 1996, 75, 11-16.	1.2	43
129	Are Butter and Cheese Rich in Monounsaturates Beneficial in Hyperlipidaemic Patients?. European Journal of Cardiovascular Prevention and Rehabilitation, 1996, 3, 441-445.	3.1	6
130	Can Genes Prevent Atherosclerosis?. JAMA - Journal of the American Medical Association, 1996, 276, 989.	3.8	8
131	Oxidized Low Density Lipoproteins in Atherogenesis: Role of Dietary Modification. Annual Review of Nutrition, 1996, 16, 51-71.	4.3	137
132	Regulation of Human Apolipoprotein A-I Gene Expression by Gramoxone. Journal of Biological Chemistry, 1997, 272, 14954-14960.	1.6	19
133	Apolipoprotein L, a New Human High Density Lipoprotein Apolipoprotein Expressed by the Pancreas. Journal of Biological Chemistry, 1997, 272, 25576-25582.	1.6	190
134	Novel Function of Lecithin-Cholesterol Acyltransferase. Journal of Biological Chemistry, 1997, 272, 16231-16239.	1.6	105
135	Chapter 29 Mode of action of lipid-lowering drugs. Principles of Medical Biology, 1997, , 561-575.	0.1	0
136	Oxidation of Human High-Density Lipoproteins by â˙™ OH and â˙™ OH/O 2 â˙™- Free Radicals. Radiation Research, 1997, 147, 721.	0.7	19
137	Evidence for a paraoxonase-independent inhibition of low-density lipoprotein oxidation by high-density lipoprotein. Atherosclerosis, 1997, 135, 193-204.	0.4	87
138	Oxidative tyrosylation of high density lipoprotein impairs biliary sterol secretion in rats. Atherosclerosis, 1997, 131, 35-41.	0.4	19
139	Cigarette Smoke Extract Inhibits Plasma Paraoxonase Activity by Modification of the Enzyme's Free Thiols. Biochemical and Biophysical Research Communications, 1997, 236, 289-293.	1.0	164
140	Elevated plasma lipid hydroperoxides in patients with coronary artery disease. American Heart Journal, 1997, 134, 572-576.	1.2	31
141	Resistance of lipoproteins from continuous ambulatory peritoneal dialysis patients to in vitro oxidation. Metabolism: Clinical and Experimental, 1997, 46, 833-839.	1.5	8
142	Oxidation of low-density lipoprotein and atherosclerosis in chronic renal failure. Medical Hypotheses, 1997, 49, 389-395.	0.8	3
143	Non-specific inhibition by human lipoproteins of endothelium dependent relaxation in rat aorta may be attributed to lipoprotein phospholipids. Cardiovascular Research, 1997, 34, 590-596.	1.8	19
144	Endothelial Cells Prevent Accumulation of Lipid Hydroperoxides in Low-Density Lipoprotein. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 3469-3474.	1.1	11

#	Article	IF	Citations
145	Niacin Decreases Removal of High-Density Lipoprotein Apolipoprotein A-I But Not Cholesterol Ester by Hep G2 Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 2020-2028.	1.1	189
146	Vitamin E/Lipid Peroxide Ratio and Susceptibility of LDL to Oxidative Modification in Nonâ€“Insulin-Dependent Diabetes Mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 1438-1446.	1.1	47
147	Plasma LDL and HDL Subspecies Are Heterogenous in Particle Content of Tocopherols and Oxygenated and Hydrocarbon Carotenoids. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 786-796.	1.1	163
148	INHIBITION OF ENDOTHELIAL CELL ADHESION MOLECULE EXPRESSION BY HIGH DENSITY LIPOPROTEINS.. Clinical and Experimental Pharmacology and Physiology, 1997, 24, 286-287.	0.9	38
149	Cholesteryl Ester Transfer Protein and Atherogenesis. Annals of the New York Academy of Sciences, 1997, 811, 178-184.	1.8	15
150	Regulation of Neutral Cholesterol Esterase Activity by Cholesterol in J774 A.1 Macrophages. Annals of the New York Academy of Sciences, 1997, 811, 471-479.	1.8	2
151	High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithinchoesteryl acyltransferase. Nature Medicine, 1997, 3, 744-749.	15.2	204
152	Î±-Tocopherol Enrichment of High-Density Lipoproteins: Stabilization of Hydroperoxides Produced During Copper Oxidation. Free Radical Biology and Medicine, 1997, 22, 185-194.	1.3	28
153	ESTROGENS AND ATHEROSCLEROSIS. Annual Review of Pharmacology and Toxicology, 1997, 37, 477-515.	4.2	145
154	Whole plasma oxidation assay as a measure of lipoprotein oxidizability. BioFactors, 1997, 6, 99-109.	2.6	33
155	Acute Coronary Syndromes: Molecular Basis for Cardiac Risk Factors. , 1997, 4, 167-175.		4
156	HDL3 exerts more powerful anti-oxidative, protective effects against copper-catalyzed LDL oxidation than HDL2. Clinical Biochemistry, 1997, 30, 221-225.	0.8	67
157	How different constituents of human plasma and low density lipoprotein determine plasma oxidizability by copper. Chemistry and Physics of Lipids, 1998, 91, 39-52.	1.5	62
158	Mechanism of high-density lipoprotein subfractions inhibiting copper-catalyzed oxidation of low-density lipoprotein. Clinical Biochemistry, 1998, 31, 537-543.	0.8	20
159	The antiatherogenic role of high-density lipoprotein cholesterol. American Journal of Cardiology, 1998, 82, 13-21.	0.7	185
160	Mechanistic studies of high-density lipoproteins. American Journal of Cardiology, 1998, 82, 42U-48U.	0.7	44
161	Defining specific goals of therapy in treating dyslipidemia in the patient with low high-density lipoprotein cholesterol. Progress in Cardiovascular Diseases, 1998, 41, 151-174.	1.6	32
162	Cytotoxic effect of low-density lipoproteins on intact, ischemic, and reperfused endothelial cells. Bulletin of Experimental Biology and Medicine, 1998, 126, 911-914.	0.3	0

#	Article	IF	Citations
163	Estradiol replacement elevates the serum and tissue levels of Î±-tocopherol in ovariectomized rats. Journal of Nutritional Biochemistry, 1998, 9, 67-74.	1.9	3
164	Cardiovascular risk factors associated with clinically isolated and diffuse atherosclerosis in Spanish patients with coronary artery disease. European Journal of Clinical Investigation, 1998, 28, 643-650.	1.7	11
165	Antiatherosclerotic potency of high density lipoprotein of different origins: a review and some new findings. Prostaglandins Leukotrienes and Essential Fatty Acids, 1998, 58, 221-230.	1.0	1
166	Strong synergistic anti-peroxidative effects of HDL3 and ascorbic acid against copper-catalyzed LDL peroxidation. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1998, 1406, 307-314.	1.8	3
167	The Effect of High Density Lipoprotein Subfractions on Endothelial Eicosanoid Secretion. Thrombosis Research, 1998, 92, 65-71.	0.8	30
168	Oxidative modification of HDL3 in vitro and its effect on PLTP-mediated phospholipid transfer. Lipids and Lipid Metabolism, 1998, 1391, 181-192.	2.6	20
169	Age-related increased susceptibility of high-density lipoproteins (HDL) to in vitro oxidation induced by Î³-radiolysis of water. FEBS Letters, 1998, 435, 153-158.	1.3	44
170	Aggressive medical therapy for the prevention and treatment of coronary artery disease. Disease-a-Month, 1998, 44, 1-40.	0.4	1
171	Oxidative stress in chronic renal failure. Free Radical Research, 1998, 29, 1-11.	1.5	83
172	Lack of Protection against Oxidative Modification of LDL by Avian HDL. Biochemical and Biophysical Research Communications, 1998, 247, 443-446.	1.0	46
173	Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis, 1998, 139, 307-315.	0.4	221
174	Dyslipoproteinaemia and hyperoxidative stress in the pathogenesis of endothelial dysfunction in non-insulin dependent diabetes mellitus: an hypothesis. Atherosclerosis, 1998, 141, 17-30.	0.4	102
175	Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis. Atherosclerosis, 1998, 141, 1-15.	0.4	386
176	Paraoxonase as a Risk Marker for Cardiovascular Disease: Facts and Hypotheses. Clinical Chemistry and Laboratory Medicine, 1998, 36, 431-41.	1.4	53
177	Factors Influencing the Ability of HDL to Inhibit Expression of Vascular Cell Adhesion Molecule-1 in Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 1450-1455.	1.1	181
178	Lipoprotein-like Phospholipid Particles Inhibit the Smooth Muscle Cell Cytotoxicity of Lysophosphatidycholine and Platelet-Activating Factor. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 13-19.	1.1	24
179	Effects of Recombinant Apolipoprotein A-I _{Milano} on Aortic Atherosclerosis in Apolipoprotein Eâ€“Deficient Mice. Circulation, 1998, 97, 780-785.	1.6	242
180	Inhibitory Effects of Lipid Oxidation on the Activity of Plasma Lecithin-Cholesterol Acyltransferase. Bioscience, Biotechnology and Biochemistry, 1998, 62, 941-946.	0.6	6

#	Article	IF	Citations
181	Paraoxonase PON1 Polymorphism Leu-Met54 Is Associated With Carotid Atherosclerosis. Stroke, 1998, 29, 2043-2048.	1.0	104
182	Apolipoprotein A-I _{Zavalla} (Leu ₁₅₉ â†'Pro). Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 1242-1247.	1.1	48
183	Familial HDL Deficiency Characterized by Hypercatabolism of Mature ApoA-I but Not ProApoA-I. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 655-664.	1.1	60
184	High-density lipoprotein particles are large in patients with variant angina. Cardiovascular Research, 1998, 37, 729-737.	1.8	15
185	Oxidation of High Density Lipoproteins. Journal of Biological Chemistry, 1998, 273, 6080-6087.	1.6	168
186	Oxidative Modification of Low-Density Lipoprotein and Atherogenetic Risk in Î²-Thalassemia. Blood, 1998, 92, 3936-3942.	0.6	67
187	Oxidation of High Density Lipoproteins. Journal of Biological Chemistry, 1998, 273, 6088-6095.	1.6	296
188	High Density Lipoproteins (HDL) and the Oxidative Hypothesis of Atherosclerosis. Clinical Chemistry and Laboratory Medicine, 1999, 37, 939-48.	1.4	55
189	High-Density Lipoproteins Differentially Modulate Cytokine-Induced Expression of E-Selectin and Cyclooxygenase-2. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 910-917.	1.1	114
190	Autoantibodies Against Oxidized Low Density Lipoprotein in Patients With Angiographically Verified Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 23-27.	1.1	185
191	Increased Atherosclerosis in ApoE and LDL Receptor Gene Knock-Out Mice as a Result of Human Cholesteryl Ester Transfer Protein Transgene Expression. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 1105-1110.	1.1	214
192	Serum Paraoxonase After Myocardial Infarction. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 330-335.	1.1	262
193	Decreased Protection by HDL From Poorly Controlled Type 2 Diabetic Subjects Against LDL Oxidation May Be Due to the Abnormal Composition of HDL. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 2226-2233.	1.1	148
194	Possible Induction of Renal Dysfunction in Patients With Lecithin:Cholesterol Acyltransferase Deficiency by Oxidized Phosphatidylcholine in Glomeruli. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 794-801.	1.1	49
195	Susceptibility of low- and high-density lipoproteins from diabetic subjects to in vitro oxidative modification. Diabetic Medicine, 1999, 16, 415-423.	1.2	16
196	Role of Group II Secretory Phospholipase A₂in Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 1284-1290.	1.1	236
197	Scavenger Receptor BI Mediates the Selective Uptake of Oxidized Cholesterol Esters by Rat Liver. Journal of Biological Chemistry, 1999, 274, 8893-8899.	1.6	70
198	Lower Plasma Levels and Accelerated Clearance of High Density Lipoprotein (HDL) and Non-HDL Cholesterol in Scavenger Receptor Class B Type I Transgenic Mice. Journal of Biological Chemistry, 1999, 274, 7165-7171.	1.6	210

#	Article	IF	Citations
199	Cholesteryl Ester Transfer Protein Corrects Dysfunctional High Density Lipoproteins and Reduces Aortic Atherosclerosis in Lecithin Cholesterol Acyltransferase Transgenic Mice. Journal of Biological Chemistry, 1999, 274, 36912-36920.	1.6	200
200	Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients. Kidney International, 1999, 56, 289-298.	2.6	75
201	Susceptibility of serum lipids to copper-induced peroxidation correlates with the level of high density lipoprotein cholesterol. Lipids, 1999, 34, 255-259.	0.7	11
202	Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation. American Journal of Cardiology, 1999, 84, 1011-1017.	0.7	125
203	Oxidative modification of high-density lipoprotein 3 induced by human polymorphonuclear neutrophils. FEBS Journal, 1999, 259, 32-39.	0.2	9
204	Association of the inflammatory state in active juvenile rheumatoid arthritis with hypo-high-density lipoproteinemia and reduced lipoprotein-associated platelet-activating factor acetylhydrolase activity. Arthritis and Rheumatism, 1999, 42, 373-383.	6.7	59
205	[4] Measurement of oxidizability of blood plasma. Methods in Enzymology, 1999, 299, 35-49.	0.4	46
206	The oxidative stress hypothesis of atherosclerosis: cause or product?. Medical Hypotheses, 1999, 53, 507-515.	0.8	16
207	Role of lecithin-cholesterol acyltransferase in the metabolism of oxidized phospholipids in plasma: studies with platelet-activating factor-acetyl hydrolase-deficient plasma. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 1999, 1439, 95-109.	1.2	52
208	Susceptibility to oxidation of copper-induced plasma lipoproteins from Japanese eel: protective effect of vitellogenin on the oxidation of very low density lipoprotein. Comparative Biochemistry and Physiology C, Comparative Pharmacology and Toxicology, 1999, 123, 1-7.	0.5	32
209	Quantity and function of high density lipoprotein as an indicator of coronary atherosclerosis. Journal of the American College of Cardiology, 1999, 33, 436-443.	1.2	56
210	Lipoprotein lipase, a key role in atherosclerosis?. FEBS Letters, 1999, 462, 1-6.	1.3	59
211	Possible role of high susceptibility of high-density lipoprotein to lipid peroxidative modification and oxidized high-density lipoprotein in genesis of coronary artery spasm. Atherosclerosis, 1999, 142, 179-184.	0.4	28
212	HDL composition and HDL antioxidant capacity in patients on regular haemodialysis. Atherosclerosis, 1999, 143, 125-133.	0.4	33
213	Constantly low HDL-cholesterol concentration relates to endothelial dysfunction and increased in vivo LDL-oxidation in healthy young men. Atherosclerosis, 1999, 147, 133-138.	0.4	131
214	Copper Oxidation ofin VitroDioleolylphosphatidylcholine-Enriched High-Density Lipoproteins: Physicochemical Features and Cholesterol Effluxing Capacity. Archives of Biochemistry and Biophysics, 1999, 362, 139-147.	1.4	9
215	Variability in .ALPHA.-Tocopherol Antioxidant Activity in the Core and Surface Layers of Low- and High-Density Lipoproteins.. Journal of Nutritional Science and Vitaminology, 1999, 45, 39-48.	0.2	10
216	Soccer players under regular training show oxidative stress but an improved plasma antioxidant status. Clinical Science, 1999, 96, 381-385.	1.8	129

#	Article	IF	Citations
217	Novel Mechanism for Endothelial Dysfunction. Circulation, 1999, 99, 3092-3095.	1.6	605
218	Fatty acid modulation of endothelial activation. American Journal of Clinical Nutrition, 2000, 71, 213S-223S.	2.2	401
219	Dietary Fat Modulates Serum Paraoxonase 1 Activity in Rats. Journal of Nutrition, 2000, 130, 2427-2433.	1.3	72
220	High-density lipoproteins inhibit fibrinogen binding on adenosine diphosphate-activated monocytes. Blood Coagulation and Fibrinolysis, 2000, 11, 505-509.	0.5	4
221	How high-density lipoprotein protects against the effects of lipid peroxidation. Current Opinion in Lipidology, 2000, 11, 383-388.	1.2	170
222	Kinetics of tryptophan oxidation in plasma lipoproteins by myeloperoxidase-generated HOCl. FEBS Journal, 2000, 267, 4137-4143.	0.2	22
223	Kinetic analysis of copper-induced peroxidation of HDL, autoaccelerated and tocopherol-mediated peroxidation. Free Radical Biology and Medicine, 2000, 29, 131-146.	1.3	33
224	Response of plasma lipids to dietary cholesterol and wine polyphenols in rats fed polyunsaturated fat diets. Lipids, 2000, 35, 991-999.	0.7	24
225	Postprandial lipemia and coronary risk. Current Atherosclerosis Reports, 2000, 2, 232-242.	2.0	34
226	High-density lipoproteins protect endothelial cells from apoptosis induced by oxidized low-density lipoproteins. Protoplasma, 2000, 211, 198-206.	1.0	2
227	Lowering Dietary Saturated Fat and Total Fat Reduces the Oxidative Susceptibility of LDL in Healthy Men and Women. Journal of Nutrition, 2000, 130, 2228-2237.	1.3	40
228	Relationship between Expression Levels and Atherogenesis in Scavenger Receptor Class B, Type I Transgenics. Journal of Biological Chemistry, 2000, 275, 20368-20373.	1.6	152
229	Tobacco Smoking Modifies Association Between Gln-Arg192 Polymorphism of Human Paraoxonase Gene and Risk of Myocardial Infarction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 2120-2126.	1.1	58
230	Hepatic and Extrahepatic Scavenger Receptors. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 1860-1872.	1.1	130
231	Combined Serum Paraoxonase Knockout/Apolipoprotein E Knockout Mice Exhibit Increased Lipoprotein Oxidation and Atherosclerosis. Journal of Biological Chemistry, 2000, 275, 17527-17535.	1.6	371
232	Paraoxonase Activity Is Reduced by a Pro-atherosclerotic Diet in Rabbits. Biochemical and Biophysical Research Communications, 2000, 269, 232-236.	1.0	85
233	Protective effect of high density lipoprotein on endothelium-dependent vasodilatation. International Journal of Cardiology, 2000, 73, 231-236.	0.8	121
234	High density lipoprotein oxidation: in vitro susceptibility and potential in vivo consequences. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2000, 1483, 217-235.	1.2	94

#	Article	IF	Citations
235	Preventing, stopping, or reversing coronary artery diseaseâ€" triglyceride-rich lipoproteins and associated lipoprotein and metabolic abnormalities: The need for recognition and treatment. Disease-a-Month, 2000, 46, 421-503.	0.4	5
236	Presence of CuZn superoxide dismutase in human serum lipoproteins. FEBS Letters, 2000, 467, 57-60.	1.3	18
237	Smoking Is Associated With Reduced Serum Paraoxonase Activity and Concentration in Patients With Coronary Artery Disease. Circulation, 2000, 101, 2252-2257.	1.6	210
238	Effect of Gemfibrozil on HDL-Associated Serum Paraoxonase Activity and Lipoprotein Profile in Patients with Hyperlipidaemia. Clinical Drug Investigation, 2000, 19, 277-282.	1.1	22
239	Endothelium-dependent and -independent functions are impaired in patients with coronary heart disease. Atherosclerosis, 2000, 149, 19-24.	0.4	92
240	Dilinoleoylphosphatidylcholine protects human low density lipoproteins against oxidation. Atherosclerosis, 2000, 152, 89-95.	0.4	34
241	The paraoxonase Leuâ€"Met54 and Glnâ€"Arg191 gene polymorphisms are not associated with the risk of coronary heart disease. Atherosclerosis, 2000, 152, 421-431.	0.4	78
242	Effects of Simvastatin on Serum Paraoxonase Activity. Clinical Drug Investigation, 2001, 21, 505-510.	1.1	13
243	Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis, 2001, 154, 87-96.	0.4	245
244	A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin. Atherosclerosis, 2001, 154, 633-640.	0.4	55
245	Relative sensitivities of plasma lecithin:cholesterol acyltransferase, platelet-activating factor acetylhydrolase, and paraoxonase to in vitro gas-phase cigarette smoke exposure. Atherosclerosis, 2001, 155, 71-78.	0.4	14
246	Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation. Atherosclerosis, 2001, 155, 229-235.	0.4	122
247	Time sequence of the inhibition of endothelial adhesion molecule expression by reconstituted high density lipoproteins. Atherosclerosis, 2001, 157, 23-29.	0.4	51
248	Human Paraoxonase-3 Is an HDL-Associated Enzyme With Biological Activity Similar to Paraoxonase-1 Protein but Is Not Regulated by Oxidized Lipids. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 542-547.	1.1	319
249	Doxazosin, an Î±1-adrenergic antihypertensive agent, decreases serum oxidized LDL. American Journal of Hypertension, 2001, 14, 267-270.	1.0	20
250	Paraoxonase Status in Coronary Heart Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1451-1457.	1.1	409
251	Paraoxonase-2 Is a Ubiquitously Expressed Protein with Antioxidant Properties and Is Capable of Preventing Cell-mediated Oxidative Modification of Low Density Lipoprotein. Journal of Biological Chemistry, 2001, 276, 44444-44449.	1.6	404
252	Simvastatin and Niacin, Antioxidant Vitamins, or the Combination for the Prevention of Coronary Disease. New England Journal of Medicine, 2001, 345, 1583-1592.	13.9	1,916

#	Article	IF	Citations
253	Red wine raises plasma HDL and preserves long-chain polyunsaturated fatty acids in rat kidney and erythrocytes. British Journal of Nutrition, 2001, 86, 189-195.	1.2	45
254	Comparison of the antioxidant effects of equine estrogens, red wine components, vitamin E, and probucol on low-density lipoprotein oxidation in postmenopausal women. Menopause, 2001, 8, 408-419.	0.8	49
255	High-density lipoprotein: Epidemiology, metabolism, and antiatherogenic effects. Disease-a-Month, 2001, 47, 365-416.	0.4	23
256	High-density lipoprotein composition and paraoxonase activity in Type I diabetes. Clinical Science, 2001, 101, 659-670.	1.8	38
257	Oxidative modification of low-density lipoproteins and the outcome of renal allografts at 11/2 years. Kidney International, 2001, 59, 2346-2356.	2.6	60
258	Oxidation of methionine residues affects the structure and stability of apolipoprotein A-I in reconstituted high density lipoprotein particles. Chemistry and Physics of Lipids, 2001, 113, 133-146.	1.5	37
259	Mitogenic Effect of Lipoproteins on Human Vascular Smooth Muscle Cells: The Impact of Hydrolysis by gr II A Phospholipase A2. Laboratory Investigation, 2001, 81, 757-765.	1.7	14
260	Effect of gemfibrozil on the composition and oxidation properties of very-low-density lipoprotein and high-density lipoprotein in patients with hypertriglyceridemia. Translational Research, 2001, 137, 414-421.	2.4	9
261	Kinetics of lipid peroxidation in mixtures of HDL and LDL, mutual effects. Free Radical Biology and Medicine, 2001, 31, 1486-1497.	1.3	42
262	Antioxidant Supplements Block the Response of HDL to Simvastatin-Niacin Therapy in Patients With Coronary Artery Disease and Low HDL. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1320-1326.	1.1	193
263	Elevation of Plasma High-Density Lipoprotein Concentration Reduces Interleukin-1â€“Induced Expression of E-Selectin in an In Vivo Model of Acute Inflammation. Circulation, 2001, 103, 108-112.	1.6	234
264	Paraoxonase and Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 473-480.	1.1	715
265	Lecithin: Cholesterol Acyltransferase Reduces the Adverse Effects of Oxidized Low-Density Lipoprotein while Incurring Damage Itself. Bioscience, Biotechnology and Biochemistry, 2001, 65, 2496-2503.	0.6	4
266	High-Density Lipoprotein Regulates Calcification of Vascular Cells. Circulation Research, 2002, 91, 570-576.	2.0	183
267	Effects of estrogen on the vascular wall: vasomotor function and inflammation. Cardiovascular Research, 2002, 55, 714-726.	1.8	85
268	High-Density Lipoprotein Restores Endothelial Function in Hypercholesterolemic Men. Circulation, 2002, 105, 1399-1402.	1.6	425
269	The pivotal role of lipoprotein lipase in atherosclerosis. Cardiovascular Research, 2002, 55, 261-269.	1.8	87
270	HDL3 Exerts a More Powerful Antiperoxidative and Protective Effect against Peroxidative Modification of LDL than HDL2 Does.. Journal of Nutritional Science and Vitaminology, 2002, 48, 278-282.	0.2	20

#	Article	IF	Citations
271	Multiple Substrates for Paraoxonase-1 during Oxidation of Phosphatidylcholine by Peroxynitrite. Biochemical and Biophysical Research Communications, 2002, 290, 391-396.	1.0	84
272	Detoxification of Oxidized LDL by Transferring Its Oxidation Product(s) to Lecithin:Cholesterol Acyltransferase. Biochemical and Biophysical Research Communications, 2002, 291, 758-763.	1.0	8
273	HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis, 2002, 161, 1-16.	0.4	511
274	Changes in LDL size and HDL concentration in normal and preeclamptic pregnancies. Atherosclerosis, 2002, 162, 425-432.	0.4	148
275	Low Serum Levels of High-density Lipoprotein Cholesterol and Hypolipidaemic Treatment. Current Medical Research and Opinion, 2002, 18, 265-268.	0.9	11
276	HDL3-related decreased serum paraoxonase (PON) activity in uremic patients: comparison with the PON1 allele polymorphism. Clinica Chimica Acta, 2002, 324, 39-44.	0.5	36
277	A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: Enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. American Heart Journal, 2002, 144, 165-172.	1.2	223
278	Determination of DNA damage induced by oxidative stress in hyperlipidemic patients. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2002, 513, 17-25.	0.9	43
279	Clinical carotid atherosclerosis. Neuroimaging Clinics of North America, 2002, 12, 403-419.	0.5	12
280	The Role of High Density Lipoproteins in Thrombosis. Scientific World Journal, The, 2002, 2, 89-95.	0.8	6
281	Significant impact of the highly informative (CA)nrepeat polymorphism of theAPOA-IIgene on the plasma APOA-II concentrations and HDL subfractions: The ECTIM study. American Journal of Medical Genetics Part A, 2002, 110, 19-24.	2.4	14
282	Lipoprotein Oxidation and its Significance for Atherosclerosis: a Mathematical Approach. Bulletin of Mathematical Biology, 2002, 64, 65-95.	0.9	85
283	Contribution of HDL-apolipoproteins to the inhibition of low density lipoprotein oxidation and lipid accumulation in macrophages. Journal of Cellular Biochemistry, 2002, 86, 258-267.	1.2	10
284	Detection of oxidized high-density lipoprotein. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 781, 331-343.	1.2	17
285	Higher antioxidant defences in plasma and low density lipoproteins from rugby players. European Journal of Clinical Investigation, 2002, 32, 818-825.	1.7	46
286	Paraoxonase Gln-Arg(192) and Leu-Met(55) gene polymorphisms and enzyme activity in a population with a low rate of coronary heart disease. Clinical Biochemistry, 2002, 35, 197-203.	0.8	46
287	High density lipoprotein can modulate the inhibitory effect of oxLDL on prostacyclin generation by rat aorta in vitro. Prostaglandins and Other Lipid Mediators, 2003, 72, 91-114.	1.0	2
288	Relation between high-density lipoprotein cholesterol and peripheral vasomotor function. American Journal of Cardiology, 2003, 92, 275-279.	0.7	88

#	Article	IF	Citations
289	Immunochemical detection of circulating oxidized high-density lipoprotein with antioxidized apolipoprotein A-I monoclonal antibody. Translational Research, 2003, 141, 378-384.	2.4	21
290	The degree of unsaturation of dietary fatty acids and the development of atherosclerosis (review). Journal of Nutritional Biochemistry, 2003, 14, 182-195.	1.9	163
292	High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis, 2003, 168, 195-211.	0.4	194
293	Low Paraoxonase Activity Predicts Coronary Events in the Caerphilly Prospective Study. Circulation, 2003, 107, 2775-2779.	1.6	385
294	Copper-induced oxidative damage on astrocytes: protective effect exerted by human high density lipoproteins. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2003, 1635, 48-54.	1.2	39
295	NF-Î²B activation in endothelial cells treated with oxidized high-density lipoprotein. Biochemical and Biophysical Research Communications, 2003, 303, 313-319.	1.0	78
296	NAD(P)H oxidase p22phox Gene C242T polymorphism and lipoprotein oxidation. Clinica Chimica Acta, 2003, 335, 101-107.	0.5	22
297	Antiatherothrombotic effects of nicotinic acid. Atherosclerosis, 2003, 171, 87-96.	0.4	78
298	Modulation of HDL metabolism by probucol in complete cholesteryl ester transfer protein deficiency. Atherosclerosis, 2003, 171, 131-136.	0.4	25
299	Optimizing probucol administration to preserve left ventricular compliance after reperfusion injury in the heterotopic rat heart isograft. Journal of Heart and Lung Transplantation, 2003, 22, 959-966.	0.3	5
300	Potential role of the interaction between equine estrogens, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) in the prevention of coronary heart and neurodegenerative diseases in postmenopausal women. Lipids in Health and Disease, 2003, 2, 4.	1.2	12
301	Structural and functional properties of human plasma high density-sized lipoprotein containing only apoE particles. Journal of Lipid Research, 2003, 44, 884-892.	2.0	48
302	Oxidized HDL. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 1488-1490.	1.1	28
303	Oxidative tyrosylation of high density lipoproteins impairs cholesterol efflux from mouse J774 macrophages: role of scavenger receptors, classes A and B. Journal of Cell Science, 2003, 116, 89-99.	1.2	29
304	Plasma Lipid Composition and LDL Oxidation. Clinical Chemistry and Laboratory Medicine, 2003, 41, 56-60.	1.4	46
305	L-4F, an Apolipoprotein A-1 Mimetic, Restores Nitric Oxide and Superoxide Anion Balance in Low-Density Lipoprotein-Treated Endothelial Cells. Circulation, 2003, 107, 1520-1524.	1.6	92
306	Lipoprotein Oxidation, Plasma Total Antioxidant Capacity and Homocysteine Level in Patients with Multiple Sclerosis. Nutritional Neuroscience, 2003, 6, 189-196.	1.5	123
307	The effects of LDL reduction and HDL augmentation on physiologic and inflammatory markers. Current Opinion in Cardiology, 2003, 18, 295-300.	0.8	20

#	Article	IF	Citations
308	Vitamin C Inhibits Lipid Oxidation in Human HDL. Journal of Nutrition, 2003, 133, 3047-3051.	1.3	47
309	Relationship between High-density Lipoprotein-cholesterol and Malondialdehyde-modified Low-density Lipoprotein Concentrations. Journal of Atherosclerosis and Thrombosis, 2003, 10, 72-78.	0.9	24
310	Are the effects of statins on HDL-cholesterol clinically relevant?. European Heart Journal Supplements, 2004, 6, C58-C63.	0.0	30
311	Metabolic Syndrome Is Associated with Elevated Oxidative Stress and Dysfunctional Dense High-Density Lipoprotein Particles Displaying Impaired Antioxidative Activity. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4963-4971.	1.8	412
312	High-Density Lipoprotein as a Key Component in the Prevention of Premature Atherosclerotic Disease in the Insulin Resistance Syndrome. Seminars in Vascular Medicine, 2004, 4, 215-223.	2.1	4
313	Protective Effect of Paraoxonase Activity in High-Density Lipoproteins against Erythrocyte Membranes Peroxidation: A Comparison between Healthy Subjects and Type 1 Diabetic Patients. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2957-2962.	1.8	102
314	Human Atherosclerotic Intima and Blood of Patients with Established Coronary Artery Disease Contain High Density Lipoprotein Damaged by Reactive Nitrogen Species. Journal of Biological Chemistry, 2004, 279, 42977-42983.	1.6	246
315	A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. Journal of Lipid Research, 2004, 45, 948-953.	2.0	200
316	Lecithin/Cholesterol Acyltransferase Induces Estradiol Esterification in High-Density Lipoprotein, Increasing Its Antioxidant Potential. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5088-5093.	1.8	25
317	Serum paraoxonase activity before and after treatment of thyrotoxicosis. Clinical Endocrinology, 2004, 60, 75-80.	1.2	23
318	Treating low HDLâ€"From bench to bedside. Clinical Biochemistry, 2004, 37, 649-659.	0.8	5
319	Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage. European Journal of Clinical Pharmacology, 2004, 60, 685-691.	0.8	78
320	The association of the PON1 Q192R polymorphism with coronary heart disease: findings from the British Women's Heart and Health cohort study and a meta-analysis. BMC Genetics, 2004, 5, 17.	2.7	63
321	The Role of Paraoxonase 1 Activity in Cardiovascular Disease. American Journal of Cardiovascular Drugs, 2004, 4, 211-217.	1.0	123
323	Rapid reversal of endothelial dysfunction in hypercholesterolemic apolipoprotein E-null mice by recombinant apolipoprotein A-IMilano-phospholipid complex. Journal of the American College of Cardiology, 2004, 44, 1311-1319.	1.2	77
324	Effect of high-density lipoprotein cholesterol levels on carotid artery geometry in a Mediterranean female population. European Journal of Cardiovascular Prevention and Rehabilitation, 2004, 11, 403-407.	3.1	1
325	Gamma radiolysis as a tool to study lipoprotein oxidation mechanisms. Biochimie, 2004, 86, 903-911.	1.3	19
326	Effects of cholesterol supplementation on antioxidant enzyme activities in rat hepatic tissues: possible implications of hepatic paraoxonase in atherogenesis. Nutrition, Metabolism and Cardiovascular Diseases, 2004, 14, 211-214.	1.1	7

#	Article	IF	Citations
327	HDL: a recipe for longevity. Atherosclerosis Supplements, 2004, 5, 25-31.	1.2	39
328	High-Density Lipoprotein Cholesterol and Coronary Heart Disease. Cardiology in Review, 2004, 12, 107-119.	0.6	57
329	ATP-binding cassette transporter AI and its role in HDL formation. Current Opinion in Lipidology, 2005, 16, 19-25.	1.2	180
330	Both HDL3 and HDL2 Exert a Powerful Anti-Oxidative and Protective Effect against Acceleration of Oxidative Modification of LDL by Ascorbic Acid. Journal of Nutritional Science and Vitaminology, 2005, 51, 75-79.	0.2	3
331	Low Frequency Regular Exercise Improves Flow-Mediated Dilatation of Subjects with Mild Hypertension. Hypertension Research, 2005, 28, 315-321.	1.5	48
332	Combined effect of probucol and insulin on cataracts of diabetic rats fed a high cholesterol diet. European Journal of Pharmacology, 2005, 513, 159-168.	1.7	6
333	Lipoprotein profile in limited systemic sclerosis. Rheumatology International, 2005, 25, 379-383.	1.5	33
334	ATP-Binding Cassette Transporter A1: A Cell Cholesterol Exporter That Protects Against Cardiovascular Disease. Physiological Reviews, 2005, 85, 1343-1372.	13.1	443
335	Thematic review series: The Immune System and Atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease?. Journal of Lipid Research, 2005, 46, 389-403.	2.0	202
336	Tyrosine 192 in Apolipoprotein A-I Is the Major Site of Nitration and Chlorination by Myeloperoxidase, but Only Chlorination Markedly Impairs ABCA1-dependent Cholesterol Transport. Journal of Biological Chemistry, 2005, 280, 5983-5993.	1.6	208
337	Iron, Lipids, and Risk of Cancer in the Framingham Offspring Cohort. American Journal of Epidemiology, 2005, 161, 1115-1122.	1.6	57
338	High-density lipoprotein inhibits migration of vascular smooth muscle cells through its sphingosine 1-phosphate component. Atherosclerosis, 2005, 178, 19-23.	0.4	69
339	Paraoxonase-1 activity modulates endothelial function in patients with peripheral arterial disease. Atherosclerosis, 2005, 183, 349-354.	0.4	58
340	Oxidative inactivation of paraoxonaseâ€"implications in diabetes mellitus and atherosclerosis. Biochimica Et Biophysica Acta - General Subjects, 2005, 1725, 213-221.	1.1	62
341	Mechanisms, Significance and Treatment of Vascular Dysfunction in Type 2 Diabetes Mellitus. Drugs, 2005, 65, 31-74.	4.9	66
342	HDL enhances oxidation of LDL in vitro in both men and women. Lipids in Health and Disease, 2005, 4, 25.	1.2	7
343	Anti-Inflammatory and Antioxidant Functions of High Density Lipoproteins. , 2006, , 399-436.		0
344	A genotype of exceptional longevity is associated with preservation of cognitive function. Neurology, 2006, 67, 2170-2175.	1.5	104

#	Article	IF	Citations
345	HDL dysfunction in obstructive sleep apnea. Atherosclerosis, 2006, 184, 377-382.	0.4	165
346	A new method for the determination of arylesterase activity in human serum using simulated body fluid. Atherosclerosis, 2006, 188, 155-159.	0.4	23
347	Association of Paraoxonase-1 Activity and Concentration With Angiographic Severity and Extent of Coronary Artery Disease. Journal of the American College of Cardiology, 2006, 47, 2429-2435.	1.2	77
348	Vitamin C preserves the cardio-protective paraoxonase activity of high-density lipoprotein during oxidant stress. Archives of Biochemistry and Biophysics, 2006, 452, 129-137.	1.4	14
349	Association between paraoxonase activity and lipid levels in patients with premature coronary artery disease. Clinica Chimica Acta, 2006, 373, 77-81.	0.5	28
350	Ambulatory blood pressure monitoring andÂendothelium-dependent vasodilation inÂtheÂelderly athletes. Biomedicine and Pharmacotherapy, 2006, 60, 443-447.	2.5	27
351	HDL capacity to inhibit LDL oxidation in well-trained triathletes. Life Sciences, 2006, 78, 3074-3081.	2.0	39
352	HOMOCYSTEINE AND MALONDIALDEHYDE AS PREDICTORS OF RESTENOSIS FOLLOWING PERCUTANEOUS CORONARY INTERVENTION. ASAIO Journal, 2006, 52, 22A.	0.9	1
353	Amphenicol and macrolide derived antibiotics inhibit paraoxonase enzyme activity in human serum and human hepatoma cells (HepG2) in vitro. Biochemistry (Moscow), 2006, 71, 46-50.	0.7	13
354	Alterations in lipoprotein defense against oxidative stress in metabolic syndrome. Current Atherosclerosis Reports, 2006, 8, 501-509.	2.0	22
355	Plasma very-low-density lipoprotein, low-density lipoprotein, and high-density lipoprotein oxidative modification induces procoagulant profiles in endogenous hypertriglyceridemia. Free Radical Biology and Medicine, 2006, 40, 1796-1803.	1.3	17
356	Differential effects of oxidized LDL on apolipoprotein AI and B synthesis in HepG2 cells. Free Radical Biology and Medicine, 2006, 41, 786-796.	1.3	4
357	Mechanisms of Dyslipoproteinemias in Systemic Lupus Erythematosus. Clinical and Developmental Immunology, 2006, 13, 203-208.	3.3	63
358	Effect of Inhibiting Cholesteryl Ester Transfer Protein on the Kinetics of High-Density Lipoprotein Cholesteryl Ester Transport in Plasma. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 884-890.	1.1	36
359	Modified Low-Density Lipoproteins and High-Density Lipoproteins. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2006, 35, 322-345.	0.5	8
360	Platelet Activation by Low Density Lipoprotein and High Density Lipoprotein. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2006, 35, 270-280.	0.5	61
361	Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis. Pharmacological Reviews, 2006, 58, 342-374.	7.1	629
362	Indoxyl Sulfate and Atherosclerotic Risk Factors in Hemodialysis Patients. American Journal of Nephrology, 2007, 27, 30-35.	1.4	98

#	Article	IF	Citations
363	Endothelial function, arterial stiffness and lipid lowering drugs. Expert Opinion on Therapeutic Targets, 2007, 11, 1143-1160.	1.5	39
364	Age-related impairment of HDL-mediated cholesterol efflux. Journal of Lipid Research, 2007, 48, 328-336.	2.0	70
365	Functional LCAT deficiency in human apolipoprotein A-I transgenic, SR-BI knockout mice. Journal of Lipid Research, 2007, 48, 1052-1061.	2.0	19
366	Continuous intake of polyphenolic compounds containing cocoa powder reduces LDL oxidative susceptibility and has beneficial effects on plasma HDL-cholesterol concentrations in humans. American Journal of Clinical Nutrition, 2007, 85, 709-717.	2.2	211
367	LDL resistance to oxidation: Effects of lipid phenotype, autologous HDL and alanine. Clinica Chimica Acta, 2007, 379, 95-100.	0.5	4
368	Assessment of paraoxonase and arylesterase activities in patients with iron deficiency anemia. Atherosclerosis, 2007, 191, 397-402.	0.4	65
369	The effect of ethanol extract of Hypericum lysimachioides on lipid profile in hypercholesterolemic rabbits and its in vitro antioxidant activity. Atherosclerosis, 2007, 192, 113-122.	0.4	47
371	Chapter 12 Recent Trends in HDL Modulating Therapies. Annual Reports in Medicinal Chemistry, 2007, , 177-191.	0.5	2
372	Revisiting niacin: reviewing the evidence. Journal of Clinical Lipidology, 2007, 1, 248-255.	0.6	13
373	Arylesterase Activity and Antioxidant Status Depend on PON1-Q192R and PON1-L55M Polymorphisms in Subjects with Increased Risk of Cardiovascular Disease Consuming Walnut-Enriched Meat. Journal of Nutrition, 2007, 137, 1783-1788.	1.3	37
374	Vascular risk factors and oxidative stress as independent predictors of asymptomatic atherosclerosis in adult patients with epilepsy. Epilepsy Research, 2007, 74, 183-192.	0.8	113
375	Serum paraoxonase and arylesterase activities for the evaluation of patients with chronic hepatitis. International Journal of Clinical Practice, 2007, 62, 1050-1055.	0.8	14
376	HDL Cholesterol: Physiology, Pathophysiology, and Management. Current Problems in Cardiology, 2007, 32, 268-314.	1.1	65
377	Plasma Protein Lipofuscin-like Fluorophores in Men with Coronary Artery Disease Treated with Statins. Archives of Medical Research, 2007, 38, 757-763.	1.5	1
378	Hepatic metabolism of oxidatively modified apo Eâ€free highâ€density lipoproteins. Liver, 1998, 18, 264-271.	0.1	1
379	Paraoxonase-1 and Cardiovascular Disease. , 2008, , 51-60.		0
380	Mild Oxidation Promotes and Advanced Oxidation Impairs Remodeling of Human High-Density Lipoprotein In Vitro. Journal of Molecular Biology, 2008, 376, 997-1007.	2.0	24
381	Vitamin C supplementation lowers serum low-density lipoprotein cholesterol and triglycerides: a meta-analysis of 13 randomized controlled trials. Journal of Chiropractic Medicine, 2008, 7, 48-58.	0.3	92

#	Article	IF	Citations
382	Beyond High-Density Lipoprotein Cholesterol Levels. Journal of the American College of Cardiology, 2008, 51, 2199-2211.	1.2	231
383	Serum paraoxonase-1 activity in Helicobacter pylori infected subjects. Atherosclerosis, 2008, 196, 270-274.	0.4	52
384	Effects of Protein Oxidation on the Structure and Stability of Model Discoidal High-Density Lipoproteins. Biochemistry, 2008, 47, 3875-3882.	1.2	34
385	Anti-atherogenic and anti-inflammatory properties of high-density lipoprotein are affected by specific antibodies in systemic lupus erythematosus. Rheumatology, 2008, 48, 26-31.	0.9	79
386	Increasing Oxidative Stress with Progressive Hyperlipidemia in Human: Relation between Malondialdehyde and Atherogenic Index. Journal of Clinical Biochemistry and Nutrition, 2008, 43, 154-158.	0.6	235
387	The role of dysfunctional HDL in atherosclerosis. Journal of Lipid Research, 2009, 50, S145-S149.	2.0	185
388	Dietary capsanthin, the main carotenoid in paprika (Capsicum annuum), alters plasma high-density lipoprotein-cholesterol levels and hepatic gene expression in rats. British Journal of Nutrition, 2009, 102, 1760-1766.	1.2	65
389	Humoral Mechanisms of Atherogenesis. Annals of the New York Academy of Sciences, 2009, 1173, 401-408.	1.8	6
390	Dysfunctional high-density lipoprotein. Current Opinion in Endocrinology, Diabetes and Obesity, 2009, 16, 156-162.	1.2	51
391	Reconstituted High-Density Lipoprotein Attenuates Platelet Function in Individuals With Type 2 Diabetes Mellitus by Promoting Cholesterol Efflux. Circulation, 2009, 120, 2095-2104.	1.6	167
392	Oxidised lowâ€density lipoprotein and arterial function in Î²â€thalassemia major. European Journal of Haematology, 2009, 82, 477-483.	1.1	9
393	The endothelial microparticle response to a high fat meal is not attenuated by prior exercise. European Journal of Applied Physiology, 2009, 106, 555-562.	1.2	32
394	The paraoxonase gene family and atherosclerosis. Current Atherosclerosis Reports, 2009, 11, 182-187.	2.0	19
395	Administration of Tomato and Paprika Beverages Modifies Hepatic Glucose and Lipid Metabolism in Mice: A DNA Microarray Analysis. Journal of Agricultural and Food Chemistry, 2009, 57, 10964-10971.	2.4	15
396	Effects of polydatin from Polygonum cuspidatum on lipid profile in hyperlipidemic rabbits. Biomedicine and Pharmacotherapy, 2009, 63, 457-462.	2.5	90
397	Multidrug-resistance-associated protein plays a protective role in menadione-induced oxidative stress in endothelial cells. Life Sciences, 2009, 84, 211-217.	2.0	19
398	Paraoxonase Variants Relate to 10-Year Risk in Coronary Artery Disease. Journal of the American College of Cardiology, 2009, 54, 1238-1245.	1.2	72
399	Studies on HDL associated enzymes under experimental hypercholesterolemia: possible modulation on selenium supplementation. Lipids in Health and Disease, 2009, 8, 55.	1.2	31

#	Article	IF	Citations
400	Modulation of paraoxonase 1 and 3 expression after moderate exercise training in the rat. Journal of Lipid Research, 2009, 50, 2036-2045.	2.0	30
401	High-density lipoproteins, inflammation and oxidative stress. Clinical Science, 2009, 116, 87-98.	1.8	134
402	Short-term effects of extended-release niacin on endothelial function in HIV-infected patients on stable antiretroviral therapy. Aids, 2010, 24, 1019-1023.	1.0	15
403	Paraoxonase Activity in Athletic Adolescents. Pediatric Exercise Science, 2010, 22, 93-104.	0.5	20
404	Oxidized LDL and its correlation with lipid profile and oxidative stress biomarkers in young healthy Spanish subjects. Journal of Physiology and Biochemistry, 2010, 66, 221-227.	1.3	23
405	Oxidative Modification and Poor Protective Activity of HDL on LDL Oxidation in Thalassemia. Lipids, 2010, 45, 627-633.	0.7	4
406	Matrix metalloproteinaseâ€9 and paraoxonase 1 Q/R192 gene polymorphisms and the risk of coronary artery stenosis in Iranian subjects. Journal of Clinical Laboratory Analysis, 2010, 24, 305-310.	0.9	18
407	Functional Change in the HDL Particle by Oxidative Modification and its Contribution to Atherogenesis. , 2010, , 215-241.		0
408	Determination of Circulating Native and Denaturated HDL Concentrations and its Clinical Implications. , 2010, , 261-275.		0
409	High-density lipoprotein metabolism and the human embryo. Human Reproduction Update, 2010, 16, 20-38.	5.2	66
410	HDL and electronegative LDL exchange anti- and pro-inflammatory properties. Journal of Lipid Research, 2010, 51, 2947-2956.	2.0	24
411	Effect of Erythrina variegata seed extract on hyperlipidemia elicited by high-fat diet in wistar rats. Journal of Pharmacy and Bioallied Sciences, 2010, 2, 350.	0.2	11
412	Effect of single bout of maximal excercise on plasma antioxidant status and paraoxonase activity in young sportsmen. Redox Report, 2010, 15, 275-281.	1.4	23
413	Relationship between paraoxonase-1 activity, carotid intima-media thickness and arterial stiffness in hypertensive patients. Journal of Human Hypertension, 2010, 24, 492-494.	1.0	17
414	Extracellular hydrophobic regions in scavenger receptor BI play a key role in mediating HDL-cholesterol transport. Archives of Biochemistry and Biophysics, 2010, 496, 132-139.	1.4	32
415	Effects of total glucosides from paeony (Paeonia lactiflora Pall) roots on experimental atherosclerosis in rats. Journal of Ethnopharmacology, 2011, 135, 469-475.	2.0	54
416	Skin autofluorescence is inversely related to HDL anti-oxidative capacity in type 2 diabetes mellitus. Atherosclerosis, 2011, 218, 102-106.	0.4	21
417	Serum paraoxonase activity and oxidative stress in patients with adult nephrotic syndrome. Atherosclerosis, 2011, 218, 243-246.	0.4	21

#	Article	IF	Citations
418	Vitamin C Alleviates Chronic Chlorpyrifos Induced Alterations in Serum Lipids and Oxidative Parameters in Male Wistar Rats. American Journal of Pharmacology and Toxicology, 2011, 6, 109-118.	0.7	14
419	Gender differences in vascular function and insulin sensitivity in young adults. Clinical Science, 2011, 120, 153-160.	1.8	30
421	Oxidized Low Density Lipoproteins-Do We Know Enough About Them?. Cardiovascular Drugs and Therapy, 2011, 25, 367-377.	1.3	28
422	Studies on Scavenger Receptors under Experimental Hypercholesterolemia: Modulation on Selenium Supplementation. Biological Trace Element Research, 2011, 143, 310-319.	1.9	4
423	Cholesteryl ester transfer protein: The controversial relation to atherosclerosis and emerging new biological roles. IUBMB Life, 2011, 63, 248-257.	1.5	41
424	Serum paraoxonase and arylesterase activities in various forms of hepatitis B virus infection. Journal of Clinical Laboratory Analysis, 2011, 25, 311-316.	0.9	18
425	Anti-inflammatory and Antioxidant Properties of HDLs Are Impaired in Type 2 Diabetes. Diabetes, 2011, 60, 2617-2623.	0.3	162
426	Associations of Cholesterol and Glucose with Cardiovascular Dysfunction in Black Africans: The SABPA Study. Clinical and Experimental Hypertension, 2011, 33, 159-166.	0.5	4
427	Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention. Expert Review of Clinical Immunology, 2011, 7, 227-241.	1.3	88
428	Antioxidant and anti-inflammatory role of paraoxonase 1: Implication in arteriosclerosis diseases. North American Journal of Medical Sciences, 2012, 4, 523.	1.7	166
429	Low Levels of Serum Paraoxonase Activities are Characteristic of Metabolic Syndrome and May Influence the Metabolic-Syndrome-Related Risk of Coronary Artery Disease. Experimental Diabetes Research, 2012, 2012, 1-9.	3.8	26
430	Preparation and Activity Analysis of Recombinant Human High-Density Lipoprotein. Assay and Drug Development Technologies, 2012, 10, 485-491.	0.6	4
431	Multidrug Resistance Associated Protein 1 together with Glutathione Plays a Protective Role against 4-Hydroxy-2-nonenal-Induced Oxidative Stress in Bovine Aortic Endothelial Cells. Biological and Pharmaceutical Bulletin, 2012, 35, 1269-1274.	0.6	4
432	Quantitative Assessment of the Influence of Paraoxonase 1 Activity and Coronary Heart Disease Risk. DNA and Cell Biology, 2012, 31, 975-982.	0.9	50
433	Effects of rosemary on lipid profile in diabetic rats. African Journal of Plant Science, 2012, 6, .	0.4	5
434	ATP-binding cassette transporter A1 and HDL metabolism: effects of fatty acids. Journal of Nutritional Biochemistry, 2012, 23, 1-7.	1.9	37
435	The two faces of Î±- and Î³-tocopherols: an in vitro and ex vivo investigation into VLDL, LDL and HDL oxidation. Journal of Nutritional Biochemistry, 2012, 23, 845-851.	1.9	20
436	Chlorogenic Acid Exhibits Cholesterol Lowering and Fatty Liver Attenuating Properties by Upâ€regulating the Gene Expression of PPARâ€Î± in Hypercholesterolemic Rats Induced with a Highâ€Cholesterol Diet. Phytotherapy Research, 2013, 27, 545-551.	2.8	172

#	Article	IF	Citations
437	Effects of modified LDL and HDL on retinal pigment epithelial cells: a role in diabetic retinopathy?. Diabetologia, 2013, 56, 2318-2328.	2.9	69
439	Aqueous extract of unripe Rubus coreanus fruit attenuates atherosclerosis by improving blood lipid profile and inhibiting NF-Î²B activation via phase II gene expression. Journal of Ethnopharmacology, 2013, 146, 515-524.	2.0	26
440	Paraoxonases. Advances in Clinical Chemistry, 2013, 59, 65-100.	1.8	29
441	Aging affects high-density lipoprotein composition and function. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2013, 1831, 1442-1448.	1.2	90
442	An effective and rapid determination by MALDI/TOF/TOF of methionine sulphoxide content of ApoAâ€Ⅰ in type 2 diabetic patients. Journal of Mass Spectrometry, 2013, 48, 105-110.	0.7	8
443	Targeting paraoxonase-1 in atherosclerosis. Expert Opinion on Therapeutic Targets, 2013, 17, 829-837.	1.5	47
444	High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease. Journal of Lipid Research, 2013, 54, 3227-3243.	2.0	132
445	Novel technique for generating macrophage foam cells for in vitro reverse cholesterol transport studies. Journal of Lipid Research, 2013, 54, 3358-3372.	2.0	20
446	Lipaemic plasma induces haemolysis in resuspended red cell concentrate. Vox Sanguinis, 2013, 104, 218-224.	0.7	13
447	‹i›Ligusticum chuanxiong‹/i› Prevents Ovariectomy-Induced Liver and Vascular Damage in Rats. The American Journal of Chinese Medicine, 2013, 41, 831-848.	1.5	17
448	Hypolipidemic effect of SR-BI gene delivery by combining cationic liposomal microbubbles and ultrasound in hypercholesterolemic rats. Molecular Medicine Reports, 2013, 7, 1965-1969.	1.1	3
449	Plasma Lipoproteins as Mediators of the Oxidative Stress Induced by UV Light in Human Skin: A Review of Biochemical and Biophysical Studies on Mechanisms of Apolipoprotein Alteration, Lipid Peroxidation, and Associated Skin Cell Responses. Oxidative Medicine and Cellular Longevity, 2013, 2013, 1-11.	1.9	6
450	<i>Olea europaea</i> Linn (Oleaceae) Fruit Pulp Exhibits Hypocholesterolemic and Hepatoprotective Effects via Regulation of Peroxisome Proliferation-Activated Receptor Alpha in High-Fat Diet-Fed Rats. Tropical Journal of Pharmaceutical Research, 2014, 13, 31.	0.2	9
451	Oxidized High-Density Lipoprotein. , 2014, , 247-272.		1
452	Effect of Switch to the Highest Dose of Rosuvastatin Versus Addâ€onâ€Statin Fenofibrate Versus Addâ€onâ€Statin Nicotinic Acid/Laropiprant on Oxidative Stress Markers in Patients with Mixed Dyslipidemia. Cardiovascular Therapeutics, 2014, 32, 139-146.	1.1	15
453	Pharmacology of conjugated equine estrogens: Efficacy, safety and mechanism of action. Journal of Steroid Biochemistry and Molecular Biology, 2014, 142, 16-29.	1.2	87
454	Lipids in health and disease. Nature, 2014, 510, 47-47.	13.7	24
455	Epalrestat increases intracellular glutathione levels in Schwann cells through transcription regulation. Redox Biology, 2014, 2, 15-21.	3.9	27

#	Article	IF	Citations
456	Glycolaldehyde induces endoplasmic reticulum stress and apoptosis in Schwann cells. Toxicology Reports, 2015, 2, 1454-1462.	1.6	8
457	How HDL protects LDL against atherogenic modification. Current Opinion in Lipidology, 2015, 26, 247-256.	1.2	34
458	Hypolipidemic effect of ethanolic extract from whole plant of Lactuca runcinata (DC.) in atherogenic diet induced hyperlipidemic rats. African Journal of Pharmacy and Pharmacology, 2015, 9, 1080-1087.	0.2	2
459	Antioxidant properties of HDL. Frontiers in Pharmacology, 2015, 6, 222.	1.6	112
460	Fatty acids composition, cholesterol and vitamin E contents of Longissimus dorsi and Semitendinosus muscles of Suino Nero Lucano pigs slaughtered at two different weights. Animal Production Science, 2015, 55, 1037.	0.6	9
461	Epalrestat increases glutathione, thioredoxin, and heme oxygenase-1 by stimulating Nrf2 pathway in endothelial cells. Redox Biology, 2015, 4, 87-96.	3.9	32
462	Serum paraoxonase activity is associated with epicardial fat tissue in renal transplant recipients. International Urology and Nephrology, 2015, 47, 1409-1414.	0.6	3
463	HDL and Atherothrombotic Vascular Disease. Handbook of Experimental Pharmacology, 2015, 224, 369-403.	0.9	24
464	Translational value of animal models of obesityâ€"Focus on dogs and cats. European Journal of Pharmacology, 2015, 759, 240-252.	1.7	36
465	Oxidized HDL and LDL in adolescents with type 2 diabetes compared to normal weight and obese peers. Journal of Diabetes and Its Complications, 2015, 29, 679-685.	1.2	28
466	Beneficial Effects of Red Yeast Rice on High-Fat Diet-Induced Obesity, Hyperlipidemia, and Fatty Liver in Mice. Journal of Medicinal Food, 2015, 18, 1095-1102.	0.8	31
467	Relation Between Monocyte to High-Density Lipoprotein Cholesterol Ratio With Presence and Severity of Isolated Coronary Artery Ectasia. American Journal of Cardiology, 2015, 116, 1685-1689.	0.7	62
468	Comparative Study of Glucose Homeostasis, Lipids and Lipoproteins, HDL Functionality, and Cardiometabolic Parameters in Modestly Severely Obese African Americans and White Americans With Prediabetes: Implications for the Metabolic Paradoxes. Diabetes Care, 2015, 38, 228-235.	4.3	13
469	Oral isotretinoin therapy of acne patients decreases serum paraoxonase-1 activity through increasing oxidative stress. Drug and Chemical Toxicology, 2015, 38, 63-66.	1.2	10
470	Protection from Cardiovascular Disease Due to Increased High-Density Lipoprotein Cholesterol in African Black Populations: Myth or Reality?. Ethnicity and Disease, 2016, 26, 553.	1.0	12
471	The influence of ApoE genotype on the lipid profile and lipoproteins during normal pregnancy in a Southern African population. African Health Sciences, 2016, 16, 853.	0.3	11
472	Metrics of High-Density Lipoprotein Function and Hospital Mortality in Acute Heart Failure Patients. PLoS ONE, 2016, 11, e0157507.	1.1	24
473	Postprandial Paraoxonase 1 Activity Following Consumption of Recommended Amounts of Mixed Meals in Healthy Males. Journal of Atherosclerosis and Thrombosis, 2016, 23, 225-232.	0.9	5

#	Article	IF	Citations
474	A potential marker of bare metal stent restenosis: monocyte count - to- HDL cholesterol ratio. BMC Cardiovascular Disorders, 2016, 16, 186.	0.7	49
475	Monocyte to HDL Cholesterol Ratio Predicts Coronary Artery Disease Severity and Future Major Cardiovascular Adverse Events in Acute Coronary Syndrome. Heart Lung and Circulation, 2016, 25, 1077-1086.	0.2	127
476	Variations in HDL-carried miR-223 and miR-135a concentrations after consumption of dietary trans fat are associated with changes in blood lipid and inflammatory markers in healthy men - an exploratory study. Epigenetics, 2016, 11, 438-448.	1.3	29
477	Ethnic differences in serum lipids and lipoproteins in overweight/obese African-American and white American women with pre-diabetes: significance of NMR-derived lipoprotein particle concentrations and sizes. BMJ Open Diabetes Research and Care, 2016, 4, e000246.	1.2	12
478	Usefulness of the monocyte-to-high-density lipoprotein cholesterol ratio to predict bare metal stent restenosis. Biomarkers in Medicine, 2016, 10, 959-966.	0.6	36
479	Chungtaejeon, a Korean fermented tea, prevents the risk of atherosclerosis in rats fed a high-fat atherogenic diet. Journal of Integrative Medicine, 2016, 14, 134-142.	1.4	28
480	Association of Monocyte-to-HDL Cholesterol Ratio with Slow Coronary Flow is Linked to Systemic Inflammation. Clinical and Applied Thrombosis/Hemostasis, 2016, 22, 476-482.	0.7	152
481	Oxidative stress and Syntax score. Herz, 2017, 42, 793-793.	0.4	0
482	Long-term treatment of clarithromycin at a low concentration improves hydrogen peroxide-induced oxidant/antioxidant imbalance in human small airway epithelial cells by increasing Nrf2 mRNA expression. BMC Pharmacology & Toxicology, 2017, 18, 15.	1.0	17
483	Dyslipidemia in systemic lupus erythematosus. Immunologic Research, 2017, 65, 543-550.	1.3	82
484	Serum Concentration of HDL Particles Predicts Mortality in Acute Heart Failure Patients. Scientific Reports, 2017, 7, 46642.	1.6	30
485	Oxidized lipoprotein lipids and atherosclerosis. Free Radical Research, 2017, 51, 439-447.	1.5	63
486	Monocyte-to-high density lipoprotein ratio (MHR) can predict the significance of angiographically intermediate coronary lesions. International Journal of the Cardiovascular Academy, 2017, 3, 16-20.	0.1	16
487	HDL structure and function is profoundly affected when stored frozen in the absence of cryoprotectants. Journal of Lipid Research, 2017, 58, 2220-2228.	2.0	27
488	High-density lipoprotein cholesterol associated with change in coronary plaque lipid burden assessed by near infrared spectroscopy. Atherosclerosis, 2017, 265, 110-116.	0.4	15
489	Association of the Monocyte to HDL Cholesterol Ratio With Thrombus Burden in Patients With ST-Segment Elevation Myocardial Infarction. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 992-997.	0.7	30
490	Disparities in Cardiovascular Disease and Type 2 Diabetes Risk Factors in Blacks and Whites: Dissecting Racial Paradox of Metabolic Syndrome. Frontiers in Endocrinology, 2017, 8, 204.	1.5	37
491	The role of cholesterol-enriched diet and paraoxonase 1 inhibition in atherosclerosis progression. Journal of Cardiovascular and Thoracic Research, 2017, 9, 133-139.	0.3	7

#	Article	IF	Citations
492	Degenerated HDL and Its Clinical Implications. , 2017, , 37-63.		0
493	Oxidized low density lipoproteins: The bridge between atherosclerosis and autoimmunity. Possible implications in accelerated atherosclerosis and for immune intervention in autoimmune rheumatic disorders. Autoimmunity Reviews, 2018, 17, 366-375.	2.5	66
494	The monocyte counts to HDL cholesterol ratio in obese and lean patients with polycystic ovary syndrome. Reproductive Biology and Endocrinology, 2018, 16, 34.	1.4	50
495	Elevated Monocyte to High-Density Lipoprotein Cholesterol Ratio and Endothelial Dysfunction in BehÃŞet Disease. Angiology, 2018, 69, 65-70.	0.8	57
496	Activity of the antioxidant enzyme paraoxonase in Argentinean children living at high altitude. Redox Report, 2018, 23, 35-40.	1.4	4
497	Protective effect of the hydroalcoholic extract of Tripodanthus acutifolius in hypercholesterolemic Wistar rats. Biomedicine and Pharmacotherapy, 2018, 97, 300-309.	2.5	2
498	Relation between Monocyte to High-Density Lipoprotein Cholesterol Ratio and Presence and Severity of Erectile Dysfunction. Aktuelle Urologie, 2018, 49, 256-261.	0.3	13
499	Feasibility of a plasma bioassay to assess oxidative protection of low-density lipoproteins by high-density lipoproteins. Journal of Clinical Lipidology, 2018, 12, 1539-1548.	0.6	17
500	Comparison of the antioxidant effects of equine estrogens, red wine components, vitamin E, and probucol on low-density lipoprotein oxidation in postmenopausal women. Menopause, 2018, 25, 1214-1223.	0.8	20
501	Low concentrations of clarithromycin upregulate cellular antioxidant enzymes and phosphorylation of extracellular signal-regulated kinase in human small airway epithelial cells. Journal of Pharmaceutical Health Care and Sciences, 2018, 4, 23.	0.4	5
502	Cross-sectional correlates of paraoxonase 1 and soluble intercellular adhesion molecule-1 in metabolic syndrome patients with and without diabetes. Therapeutic Advances in Endocrinology and Metabolism, 2018, 9, 303-310.	1.4	1
503	Pharmacological Intervention to Modulate HDL: What Do We Target?. Frontiers in Pharmacology, 2017, 8, 989.	1.6	47
504	Predictive value of lymphocyte to monocyte ratio and monocyte to high-density lipoprotein ratio for acute deep vein thrombosis after total joint arthroplasty: a retrospective study. Journal of Orthopaedic Surgery and Research, 2018, 13, 211.	0.9	18
505	The impact of monocyte to high-density lipoprotein ratio on reduced renal function: insights from a large population. Biomarkers in Medicine, 2019, 13, 773-783.	0.6	12
506	High-Density Lipoprotein Function and Dysfunction in Health and Disease. Cardiovascular Drugs and Therapy, 2019, 33, 207-219.	1.3	69
507	Assessing the performance of monocyte to high-density lipoprotein ratio for predicting ischemic stroke: insights from a population-based Chinese cohort. Lipids in Health and Disease, 2019, 18, 127.	1.2	32
508	Probucol Slows the Progression of Cataracts in Streptozotocin-Induced Hyperglycemic Rats. Pharmacology, 2019, 103, 212-219.	0.9	4
509	Royal jelly attenuates nonalcoholic fatty liver disease by inhibiting oxidative stress and regulating the expression of circadian genes in ovariectomized rats. Journal of Food Biochemistry, 2020, 44, e13138.	1.2	15

#	Article	IF	Citations
510	Can decreased monocyte to <scp>HDL</scp> â€cholesterol ratio be a marker indicating the antiâ€inflammatory effect of the colchicine in BehÃ§et's disease? A preliminary study. Dermatologic Therapy, 2020, 33, e14013.	0.8	7
511	Candidate Gene Analysis Reveals Strong Association of CETP Variants With High Density Lipoprotein Cholesterol and PCSK9 Variants With Low Density Lipoprotein Cholesterol in Ghanaian Adults: An AWI-Gen Sub-Study. Frontiers in Genetics, 2020, 11, 456661.	1.1	4
512	Investigation of monocyte HDL ratio as an indicator of inflammation and complete blood count parameters in patients with acne vulgaris. International Journal of Clinical Practice, 2020, 74, e13639.	0.8	8
513	High-density lipoproteins are a potential therapeutic target for age-related macular degeneration. Journal of Biological Chemistry, 2020, 295, 13601-13616.	1.6	20
514	Can monocyte to HDL cholesterol ratio and monocyte to lymphocyte ratio be markers for inflammation and oxidative stress in patients with vitiligo? A preliminary study. Archives of Dermatological Research, 2020, 313, 491-498.	1.1	22
515	Impact of monocyte to high-density lipoprotein ratio on prevalent hyperuricemia: findings from a rural Chinese population. Lipids in Health and Disease, 2020, 19, 48.	1.2	9
516	Evaluation of Daily Laurus nobilis Tea Consumption on Lipid Profile Biomarkers in Healthy Volunteers. Journal of the American College of Nutrition, 2020, 39, 733-738.	1.1	8
517	The Relationship Between Heavy Metal Exposure, Trace Element Level, and Monocyte to HDL Cholesterol Ratio with Gestational Diabetes Mellitus. Biological Trace Element Research, 2021, 199, 1306-1315.	1.9	32
518	Monocyte to highâ€density lipoprotein cholesterol and lymphocyte to monocyte ratios are predictors of inâ€hospital and longâ€term mortality in patients with acute coronary syndrome. International Journal of Clinical Practice, 2021, 75, e13973.	0.8	15
519	A Nomogram to Predict Lifestyle Factors for Recurrence of Large-Vessel Ischemic Stroke. Risk Management and Healthcare Policy, 2021, Volume 14, 365-377.	1.2	3
520	Effect of highâ€density lipoprotein on penile erection: A crossâ€sectional study. Andrologia, 2021, 53, e13979.	1.0	3
521	Changing Perspectives on HDL: From Simple Quantity Measurements to Functional Quality Assessment. Journal of Lipids, 2021, 2021, 1-11.	1.9	15
522	Monocyte/HDL ratio in women with polycystic ovary syndrome and healthy controls. Anatolian Current Medical Journal:, 2021, 3, 98-103.	0.1	2
523	High-density lipoproteins, reverse cholesterol transport and atherogenesis. Nature Reviews Cardiology, 2021, 18, 712-723.	6.1	91
524	The association between monocyte HDL ratio andÂalbuminuria in diabetic nephropathy. Pakistan Journal of Medical Sciences, 2021, 37, 1128-1132.	0.3	4
525	Impact of monocyte to high-density lipoprotein ratio on the identification of prevalent coronary heart disease: insights from a general population. Postgraduate Medicine, 2021, 133, 822-829.	0.9	4
526	Intestinal and Hepatic Uptake of Dietary Peroxidized Lipids and Their Decomposition Products, and Their Subsequent Effects on Apolipoprotein A1 and Paraoxonase1. Antioxidants, 2021, 10, 1258.	2.2	2
527	Antioxidant properties of anthocyanins and their mechanism of action in atherosclerosis. Free Radical Biology and Medicine, 2021, 172, 152-166.	1.3	77

#	Article	IF	Citations
528	From Green Technology to Functional Olive Oils: Assessing the Best Combination of Olive Tree-Related Extracts with Complementary Bioactivities. Antioxidants, 2021, 10, 202.	2.2	6
530	Alcohol, Free Radicals and Antioxidants. Novartis Foundation Symposium, 1998, 216, 51-67.	1.2	21
531	Modification of Biochemical and Cellular Processes in the Development of Atherosclerosis by Red Wine. , 2006, , 475-494.		2
532	High-Density Lipoprotein Metabolism. , 2011, , 93-111.		1
533	Pathophysiology of Atherosclerosis. , 2000, , 85-105.		7
534	The Human Serum Paraoxonase Polymorphism and Atherosclerosis. , 1994, , 65-73.		9
535	High-Density Lipoproteins. , 2007, , 159-199.		1
536	Functionality of HDL: Antioxidation and Detoxifying Effects. Handbook of Experimental Pharmacology, 2015, 224, 207-228.	0.9	44
537	Reverse Cholesterol Transport. Developments in Cardiovascular Medicine, 1994, , 351-369.	0.1	2
538	Lipoprotein composition in NIDDM: effects of dietary oleic acid on the composition, oxidisability and function of low and high density lipoproteins. Diabetologia, 1996, 39, 667-676.	2.9	6
539	Acetylated low density lipoprotein reduces its ligand activity for the scavenger receptor after interaction with reconstituted high density lipoprotein.. Journal of Biological Chemistry, 1994, 269, 5264-5269.	1.6	65
540	LCAT facilitates transacylation of 17Î²-estradiol in the presence of HDL3 subfraction. Journal of Lipid Research, 2002, 43, 392-397.	2.0	25
541	Apolipoprotein L gene family: tissue-specific expression, splicing, promoter regions; discovery of a new gene. Journal of Lipid Research, 2001, 42, 620-630.	2.0	118
542	Dietary oxidized fatty acids may enhance intestinal apolipoprotein A-I production. Journal of Lipid Research, 2002, 43, 557-564.	2.0	27
543	Regulation of human apolipoprotein A-I gene expression by equine estrogens. Journal of Lipid Research, 2001, 42, 1789-1800.	2.0	21
544	A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. Journal of Lipid Research, 2001, 42, 1308-1317.	2.0	292
545	Comparative analysis of lipid composition of normal and acute-phase high density lipoproteins. Journal of Lipid Research, 2000, 41, 1035-1047.	2.0	108
546	Lipoproteins are substrates for human secretory group IIA phospholipase A2: preferential hydrolysis of acute phase HDL. Journal of Lipid Research, 1998, 39, 2150-2160.	2.0	81

#	Article	IF	Citations
547	Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Qâ†'R genetic polymorphism. Journal of Lipid Research, 1999, 40, 133-139.	2.0	110
548	Plasma apolipoprotein L concentrations correlate with plasma triglycerides and cholesterol levels in normolipidemic, hyperlipidemic, and diabetic subjects. Journal of Lipid Research, 2000, 41, 1231-1236.	2.0	63
549	Human plasma CETP deficiency: identification of a novel mutation in exon 9 of the CETP gene in a Caucasian subject from North America. Journal of Lipid Research, 1998, 39, 442-456.	2.0	40
550	Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high density lipoprotein metabolism.. Journal of Lipid Research, 1994, 35, 2083-2093.	2.0	113
551	HDL antioxidant effects as assessed using a nonexchangeable probe to monitor particle-specific peroxidative stress in LDL-HDL mixtures.. Journal of Lipid Research, 1995, 36, 2580-2589.	2.0	25
552	Physiologic mechanisms for reduced apolipoprotein A-I concentrations associated with low levels of high density lipoprotein cholesterol in patients with normal plasma lipids.. Journal of Lipid Research, 1992, 33, 1527-1539.	2.0	62
553	Site-specific methionine sulfoxide formation is the structural basis of chromatographic heterogeneity of apolipoproteins A-I, C-II, and C-III.. Journal of Lipid Research, 1991, 32, 1465-1476.	2.0	76
554	Minimally oxidized LDL is a potent inhibitor of lecithin:cholesterol acyltransferase activity. Journal of Lipid Research, 1996, 37, 1012-1021.	2.0	50
555	An elevated monocyte-to-high-density lipoproteinâ€“cholesterol ratio is associated with mortality in patients with coronary artery disease who have undergone PCI. Bioscience Reports, 2020, 40, .	1.1	14
556	The Yin and Yang of Oxidation in the Development of the Fatty Streak. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 831-842.	1.1	553
557	Cholesterol-Mediated Changes of Neutral Cholesterol Esterase Activity in Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 3033-3040.	1.1	16
558	Effect of 17Î²-Estradiol on Plasma Lipids and LDL Oxidation in Postmenopausal Women With Type II Diabetes Mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 324-330.	1.1	60
559	Genetic Polymorphism of Paraoxonase and the Risk of Coronary Heart Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 1067-1073.	1.1	159
560	Atherosclerosis: Basic Mechanisms. Circulation, 1995, 91, 2488-2496.	1.6	1,387
561	Effects of Adenovirus-Mediated Human Apo A-I Gene Transfer on Neointima Formation After Endothelial Denudation in Apo Eâ€“Deficient Mice. Circulation, 1997, 96, 4349-4356.	1.6	73
562	Nitric Oxide Regulates Monocyte Chemotactic Protein-1. Circulation, 1997, 96, 934-940.	1.6	170
563	Minimally modified low density lipoprotein is biologically active in vivo in mice.. Journal of Clinical Investigation, 1991, 87, 2253-2257.	3.9	198
564	Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency.. Journal of Clinical Investigation, 1993, 92, 1650-1658.	3.9	143

#	Article	IF	Citations
565	Apolipoprotein A-I Q[-2]X causing isolated apolipoprotein A-I deficiency in a family with analphalipoproteinemia.. Journal of Clinical Investigation, 1994, 93, 223-229.	3.9	103
566	Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein.. Journal of Clinical Investigation, 1995, 95, 774-782.	3.9	369
567	Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells.. Journal of Clinical Investigation, 1995, 96, 2322-2330.	3.9	288
568	Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein.. Journal of Clinical Investigation, 1995, 96, 2882-2891.	3.9	1,012
569	Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model.. Journal of Clinical Investigation, 1996, 97, 1630-1639.	3.9	227
570	Endotoxin and cytokines decrease serum levels and extra hepatic protein and mRNA levels of cholesteryl ester transfer protein in syrian hamsters.. Journal of Clinical Investigation, 1996, 97, 2585-2592.	3.9	76
571	Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein AI gene.. Journal of Clinical Investigation, 1996, 97, 2714-2721.	3.9	97
572	Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio.. Journal of Clinical Investigation, 1997, 99, 2005-2019.	3.9	271
573	Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles.. Journal of Clinical Investigation, 1997, 100, 464-474.	3.9	160
574	High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. Journal of Clinical Investigation, 1999, 103, 219-227.	3.9	197
575	Serum amyloid A impairs the antiinflammatory properties of HDL. Journal of Clinical Investigation, 2015, 126, 266-281.	3.9	128
576	Comments on Contemporary Methods of Oxygen and Nitrogen Free Radical Detection. , 2005, , 1-284.		1
577	Anti-Inflammatory and Antioxidant Effects of Acetyl-L-Carnitine on Atherosclerotic Rats. Medical Science Monitor, 2020, 26, e920250.	0.5	19
578	The relationship between monocyte to high-density lipoprotein cholesterol ratio and diabetic nephropathy. Pakistan Journal of Medical Sciences, 2019, 35, 1081-1086.	0.3	20
579	A Cholesteryl Ester Transfer Protein Gene Mutation and Vascular Disease in Dialysis Patients. Journal of the American Society of Nephrology: JASN, 1999, 10, 294-299.	3.0	15
580	Biological Consequences of Dysfunctional HDL. Current Medicinal Chemistry, 2019, 26, 1644-1664.	1.2	65
581	Humoral Immunity Against HDL Particle: A New Perspective in Cardiovascular Diseases?. Current Pharmaceutical Design, 2019, 25, 3128-3146.	0.9	10
582	Oxidative status and paraoxonase activity in children with asthma. Clinical and Investigative Medicine, 2009, 32, 327.	0.3	32

#	Article	IF	Citations
583	Are Monocyte/HDL, Lymphocyte/Monocyte and Neutrophil/Lymphocyte Ratios Prognostic or Follow-up Markers in Ischemic Cerebrovascular Patients?. Journal of Basic and Clinical Health Sciences, 0, , .	0.2	2
584	High-Density Lipoprotein Cholesterol. , 2016, , 321-366.		2
585	High-Density Lipoprotein Cholesterol. Fundamental and Clinical Cardiology, 2006, , 295-340.	0.0	2
586	Citrulline increases cholesterol efflux from macrophages in vitro and ex vivo via ATP-binding cassette transporters. Journal of Clinical Biochemistry and Nutrition, 2014, 55, 32-39.	0.6	12
587	Long-Term Callisthenic Exercise-Related Changes in Blood Lipids, Homocysteine, Nitric Oxide Levels and Body Composition in Middle-Aged Healthy Sedentary Women. Chinese Journal of Physiology, 2012, 55, 202-209.	0.4	23
588	Increased Oxidant Stress and Inflammation in Patients with Chronic Schizophrenia. International Journal of Clinical Medicine, 2012, 03, 368-376.	0.1	11
589	HDL2 Can Inhibit Further Oxidative Modification of Partially Oxidized LDL. Journal of Atherosclerosis and Thrombosis, 2010, 17, 229-234.	0.9	3
590	High density lipoproteins and oxidative stress in breast cancer. Lipids in Health and Disease, 2021, 20, 143.	1.2	22
591	High-Density Lipoprotein Metabolism. , 2000, , 111-126.		0
592	High-Density Lipoprotein Metabolism. , 2003, , 115-131.		0
593	KÃ¶pek genÃ§lik hastalÄ±ÄŸÄ±nÄ±n sinirsel formundaki kÃ¶peklerin plazmasÄ±nda vitamin A ve beta-karotin dÃ¼zeylerindeki deÄŸiÅŸiklikler. Ankara Universitesi Veteriner Fakultesi Dergisi, 2006, 50, 1-1.	0.4	0
594	Avances en el conocimiento y manejo de las dislipoproteinemias. Anales De La Facultad De Medicina, 2013, 64, 119.	0.0	0
595	High-Density Lipoprotein Functions: Lessons from the Proteomic Approach. Journal of Glycomics & Lipidomics, 2014, 04, .	0.4	0
596	Study on Effects of Food Factors and Anti-atherogenic Lipoprotein Function. Nihon EiyÅ•ShokuryÅ•Gakkai Shi = Nippon EiyÅ•ShokuryÅ•Gakkaishi = Journal of Japanese Society of Nutrition and Food Science, 2014, 67, 3-8.	0.2	0
597	Experimental and Clinical Evidence for a Protective Role of High-Density Lipoprotein in Coronary Heart Disease. Medical Science Symposia Series, 1993, , 333-338.	0.0	0
598	An in Vitro Approach to the Study of Inflammatory Reactions in Atherosclerosis. , 1993, , 349-363.		0
599	Oral Contraceptives and Plasma Lipoprotein Metabolism. CPOBGYN Clinical Perspectives in Obstetrics and Gynecology, 1993, , 34-41.	0.1	1
600	Oxidative Stress, Cell Activation and Viral Infection. , 1994, , .		9

#	Article	IF	Citations
601	HDLC as a therapeutic target in coronary disease: current concepts and future directions. Developments in Cardiovascular Medicine, 1995, , 29-42.	0.1	0
602	Oxidation of low density lipoprotein (LDL) by cells. , 1995, , 65-81.		0
603	Enzymes and Proteins that are Associated with High Density Lipoprotein and their Role in the Anti-Inflammatory Capacity of HDL. Medical Science Symposia Series, 1996, , 599-601.	0.0	0
604	Paraoxonase 192Gln-Arg polymorphism in the patients with coronary artery disease and cerebral infarction. The Journal of Japan Atherosclerosis Society, 1998, 26, 111-116.	0.0	0
605	Oxidative Modification of Low-Density Lipoprotein and Atherogenetic Risk in Î²-Thalassemia. Blood, 1998, 92, 3936-3942.	0.6	1
606	Lipoproteins and Apoproteins. Developments in Cardiovascular Medicine, 1999, , 28-68.	0.1	0
607	Hormone Replacement Therapy for Prevention or Treatment of Atherosclerosis in Postmenopausal Women. Sunhwan'gi, 1999, 29, 639.	0.3	0
608	A Closer Look at Cardioprotective Function of HDL: Revise the HDL â€“ Cholesterol Hypothesis?. Indonesian Biomedical Journal, 2014, 6, 17.	0.2	0
609	Sub-chronic Effect of Methanol-Dichloromethane Stem Bark Extract of Stemonocoleus micranthus Harms. (Fabaceae) on Lipid Profile and Histology of Liver and Kidney of Rats. Journal of Pharmacognosy & Natural Products, 2017, 03, .	0.4	2
610	Effect ofGinkgo bilobaExtract (EGb 761) on Serum Cholesterol Levels in Wild-type C57Bl/6 Mice. Biomedical Science Letters, 2017, 23, 80-88.	0.0	0
611	Association of the Monocyte to HDL Cholesterol Ratio With Coronary Artery Disease Severity in Patients With Acute Coronary Syndrome. International Journal of ChemTech Research, 2018, 11, 95-102.	0.1	0
612	Effects of Minocycline on H2O2-induced Cell Death and Interleukin-8 Production in Human Small Airway Epithelial Cells. International Journal of Pharmacology, 2019, 15, 509-514.	0.1	1
613	Monosit yÃ¼ksek/ dansiteli lipoprotein oranÄ± ve yÃ¼ksek sensiviteli c- reaktif protein deÄŸerlerinin izole koroner arter ektazisi ile iliÅŸkisi. Turkish Journal of Clinics and Laboratory, 0, , .	0.2	0
614	Serum Amyloid A and AA Amyloidosis. , 0, , 241-256.		0
615	Apolipoprotein AI-derived pulmonary vascular amyloid in aged dogs. American Journal of Pathology, 1995, 147, 1311-7.	1.9	15
618	Paraoxonase-1 polymorphisms and cerebral ischemic stroke: a pilot study in mexican patients. Colombia Medica, 2018, 49, 223-227.	0.7	2
619	1H-NMR Plasma Lipoproteins Profile Analysis Reveals Lipid Metabolism Alterations in HER2-Positive Breast Cancer Patients. Cancers, 2021, 13, 5845.	1.7	6
620	Role of epicardial fat thickness for prediction of proliferative diabetic retinopathy. International Journal of Diabetes in Developing Countries, 2023, 43, 20-24.	0.3	2

#	Article	IF	Citations
621	HDL Is Not Dead Yet. Biomedicines, 2022, 10, 128.	1.4	8
622	YENÄ° KARDÄ°YOVASKÃœLER RÄ°SK BELÄ°RTEÃ‡LERÄ° PLAZMA ATEROJENÄ°K Ä°NDEKSÄ°, NÃ–TROFÄ°L / LENFOSÄ°T ORANI VE MONOSİT HDL ORANI OBEZİTEDE NASIL ETKİLENMEKTEDİR ? KESİTSEL RETROSPEKTİF BİR ÇALIŞMA. Kocatepe Tıp Dergisi, 2022, 23, 1-6.	0.0	0
623	Induction of Sirtuin1 Activity in SH-SY5Y Cells by Cyanidin-3-O-Glucocide Induced. Pharmacology & Pharmacy, 2022, 13, 35-48.	0.2	1
624	S-Nitrosylation of Paraxonase 1 (PON1) Elevates Its Hydrolytic and Antioxidant Activities. Biomolecules, 2022, 12, 414.	1.8	0
625	Evaluation of Inflammatory Hematological Ratios (NLR, PLR, MLR and Monocyte/HDL-Cholesterol Ratio) in Obese Adolescents. Iberoamerican Journal of Medicine, 0, , 11-17.	0.1	1
627	Fusobacterium nucleatum Accelerates Atherosclerosis via Macrophage-Driven Aberrant Proinflammatory Response and Lipid Metabolism. Frontiers in Microbiology, 2022, 13, 798685.	1.5	22
628	Exercise training and vascular function in postmenopausal individuals: a systematic review and meta-analysis. Menopause, 2022, 29, 982-992.	0.8	3
630	Comparative Susceptibility to Oxidation of Different Classes of Blood Plasma Lipoproteins. Biochemistry (Moscow), 2022, 87, 1335-1341.	0.7	2
631	The monocyte to high-density lipoprotein cholesterol ratio is a risk factor for frequent premature ventricular complexes: a retrospective cohort study. Lipids in Health and Disease, 2022, 21, .	1.2	1
632	The relationship between monocyte/HDL cholesterol ratio and chronic kidney disease stages, single center study. , 0, , .		0
633	Paraoxonase 1 and atherosclerosis. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	8
634	Investigation of the monocyte/HDL cholesterol, neutrophil/HDL cholesterol, and lymphocyte/HDL cholesterol ratios as new inflammatory markers in rosacea. Turkderm, 0, , .	0.0	0
635	Tussilagone ameliorates highâ€fat dietâ€induced hepatic steatosis by enhancing energy metabolism and antioxidant activity. Phytotherapy Research, 0, , .	2.8	0
636	Evaluation of the relationship between monocyte to high-density lipoprotein cholesterol ratio and thrombus burden in patients with deep vein thrombosis. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2023, 69, .	0.3	2